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Abstract 
Introduction: Since Human Immunodeficiency Virus (HIV)-1 was determined to be the 
etiological agent behind acquired immunodeficiency syndrome (AIDS) in 1983, numerous 
attempts at a cure have been made; however, none have been effective. One of the primary 
roadblocks in achieving a cure is a transcriptionally-silent latent reservoir of memory CD4+ T 
cells harboring HIV provirus. Combined antiretroviral therapy (cART) inhibits actively 
replicating virus by interfering with various stages of the replication cycle. Therefore, non-
replicative viruses–like the proviruses found in latently infected cells–are hidden from the 
actions of continued antiretroviral therapy. As a result, cART discontinuation or treatment 
holidays can result in rapid viral recrudescence within days to weeks. It is thought that 
latency is established when HIV infects CD4 T cells that are transitioning from effector to 
memory status, which effectively traps the virus in an environment that is not conducive to 
replication due to the low metabolic activity characteristic of these cells at G0. During latency 
reversal, it is believed that the provirus undergoes transcriptional reactivation, allowing HIV-
1 to replicate and produce infectious progeny virus that can be targeted by cART. However, a 
significant hurdle against the development of a vaccine against HIV is the immense viral 
diversity within each infected individual. A vaccine preparation should therefore encompass 
a near-complete repertoire of viral quasispecies to increase antigen coverage for maximal 
reactivation. Based on this, our group has developed a genetically diverse virus-like particle 
(VLP)-based vaccine, which is thought to be capable of activating a diverse array of cognate 
HIV-specific CD4+ T cells. These VLPs are morphologically and enzymatically identical to 
wild-type HIV-1; however, it contains several mutations that abrogate reverse transcription, 
integration, and viral RNA packaging.  
Methodology: Antigenicity of virus particles (VP) and VLPs were determined as a function 
of i) TNFα secretion measured in cell culture supernatant of HIV– peripheral blood 
mononuclear cells (PBMC) and ii) NF-κB and interferon regulatory factor (IRF) activation. 
Following an ex vivo DC-T cell co-culture assay, induced HIV RNA from recrudescent virus 
was quantified in cell culture supernatants following latency reversal and using an in-house 
developed qRT-PCR assay specific for the 5’ region of HIV RNA. In addition, T cell 
activation was measured as a function of IFN-γ secretion using a commercially available 
ELISpot kit. To determine if immunostimulatory RNA could be preferentially packaged into 
VLP, 293T cells were co-transfected with a VLP-encoding plasmid and immunostimulatory 
RNA-encoding plasmid. The adjuvanted VLPs were then concentrated by a combination of 
filtration and ultra-centrifugation before purified VLPs were assayed for p24 and RNA 
content. Immunostimulatory potential of these RNA were measured as a function of NF-κB 
and IRF activation in THP-1 cells, and TNF-α and IFN-α secretion in HIV– PBMC.  
Results: VPs induced greater TNFα secretion than VLPs in HIV– PBMC, supporting 
observations of VPs inducing greater increases in NF-κB and IRF activation compared to 
VLP. In addition, these VPs induced greater latency reversal in HIV+ PBMC, as a function of 
increased CD4+ T cell activation and increased HIV RNA in culture supernatant following 
latency reversal. We therefore engineered immunostimulatory RNA that can be packaged 
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into VLPs and found that these RNAs augmented VLP antigenicity in PBMC and THP-1 
cells in a manner that was dependent on RNA recognition by intracellular pattern recognition 
receptors.  
 
Lay Summary: Since Human Immunodeficiency Virus (HIV)-1 was determined to be the 
etiological agent behind acquired immunodeficiency syndrome (AIDS) in 1983, numerous 
attempts at a cure have been made; however, none have been effective. One of the primary 
roadblocks in achieving a cure is a transcriptionally-silent latent reservoir of memory CD4+ 
T cells harboring HIV provirus. Combined antiretroviral therapy (cART) inhibits actively 
replicating virus by interfering with various stages of the replication cycle. Therefore, non-
replicative viruses–like the proviruses found in latently infected cells–are hidden from the 
actions of continued antiretroviral therapy. As a result, cART discontinuation or treatment 
holidays can result in rapid viral recrudescence within days to weeks. Our group has 
developed a genetically diverse virus-like particle (VLP)-based vaccine, which is thought to 
be capable of activating this reservoir. These VLPs are morphologically and enzymatically 
identical to wild-type HIV-1; however, it contains several mutations that abrogate reverse 
transcription, integration, and viral RNA packaging. In this thesis, we show that virally 
packaged RNA within these particles can augment VLP antigenicity and latency reversal. 
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Chapter 1 – Introduction 
 
1.1 Macroscopic Characteristics of HIV-1  
1.1.1 The History of HIV  
In 1984, a seminal study was published that implicated Human Immunodeficiency Virus 
1 (HIV-1)–originally characterized as Human T Lymphotropic Virus III (HTLV-III)–as 
the etiological agent of acquired immunodeficiency syndrome (AIDS)1. Just a year 
before, Montagnier and his group isolated the virus from a patient at risk of AIDS, and 
was subsequently awarded the Nobel prize in Physiology and Medicine for their findings 
in 2008 2,3. The earliest documented case of HIV infection traces back to a preserved 
plasma sample originating from a man living in the Belgian Congo city of Leopoldville in 
19594. It is here that the first zoonotic transmission of a simian immunodeficiency viruses 
(SIV) into the human population, from non-human primates, is thought to have occurred5. 
There are over 40 different SIV strains that are endemic to non-human primate 
populations6. Therefore, the most plausible cause for these cross-over events stem from 
humans encountering contaminated blood or tissues from infected animals. The local 
practices of hunting and butchering primates for bushmeat therefore offers the most 
reasonable antecedent7. The reason behind the emergence of HIV as a pandemic agent of 
disease lay within the demographic data of Leopoldville in 1959. Urban city centers, like 
Leopoldville, in west central Africa underwent unprecedented levels of urban expansion 
in the 1960s and corresponded with significant movements of human populations8. At the 
time, Leopoldville was the largest city center in the region, and had several major routes 
of travel and commerce. This is believed to have been a significant driving force behind 
the stealthy dissemination of the virus across the globe. In 1984, across the Atlantic 
Ocean, an increasing number of men who have sex with men (MSM) in America were 
beginning to suffer from symptoms of an immune deficiency disorder, characterized by 
defective T cell immunity. The immune deficiency disorder among MSM populations 
was subsequently named gay-related immune deficiency (GRID)9. However, later that 
same year, HIV was identified as the etiological agent behind the enigmatic 
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immunodeficiency disorders. Phylogenetic analyses of HIV sequences from across the 
globe revealed four distinct HIV lineages: M, N, O, and P, each of which was a product 
of an independent cross-species transmission event of SIV into humans10.  
1.1.2 The Global Diversity of the HIV Pandemic  
Three out of the four lineages of HIV, group N, O, and P, have not disseminated across the 
globe, but are instead rare, and localized to certain west and central African countries, such 
as Gabon and Cameroon6. However, the pandemic group M lineage that originated from 
Leopoldville, continues to dominate world-wide infections. As the virus encountered 
different human populations in distinct geographical areas, independent genetic 
bottlenecks–termed founder events–were initiated. This is in part, due to the diverse 
selective pressures exerted by the recipient tissue and transmission fluid11. As a result of 
these factors, coupled with the high error rate of the viral RNA-dependent DNA 
polymerase and high viral turnover12,13, nine genetically distinct subtypes (A-D, F-H, J, 
and K) appeared across the globe14. Africa, the epicenter of infection, holds the greatest 
viral genetic diversity. Subtype C predominates in southern Africa15,16, whereas subtype A 
predominates in eastern Africa while subtypes C and D occasionally co-circulate17,18. West 
and central Africa are inundated with several circulating recombinant forms (CRF) of the 
virus19. In North America, Europe, and Australia, subtype B predominates20–22. Likewise, 
in South America, subtype B predominates; however, there has been recent increases in 
subtype C infections23. Asia has been described as a hotbed for the emergence of 
recombinant viral strains. In fact, there are more CRFs identified in China than any other 
country in the world24. While these CRFs predominate eastern and southeastern Asia, 
subtype A is prevalent in Russia and other countries that were formally part of the Soviet 
Union25. In south Asian countries, subtype C is found to predominate26. On a global scale, 
subtype C represents approximately 46.6% of infections, whereas subtypes A and B 
represent approximately 10.2% and 12.1%, respectively27.  
1.1.3 HIV Transmission Routes  
Nearly 70% of HIV-1 transmission events occur during heterosexual intercourse as a result 
of contacting semen and/or blood from infected individuals28. The other 30% of 
transmission events mostly correspond to three alternate transmission routes. The first of 
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which is encountering contaminated rectal fluids during anal intercourse amongst MSM 
populations. Secondly, vertical transmission of the virus from mother to infant in utero, or 
through contact with breastmilk from infected mothers. Thirdly, direct intravenous 
inoculation of live HIV from infected individuals can be facilitated by needle sharing 
practices amongst populations of intravenous drug users29.  
1.2 Microscopic Properties of HIV-1 
1.2.1 The Structure and Genomic Organization of HIV-1 
HIV-1 belongs to the Retroviridae family and is a member of the Lentivirinae genus. Viral 
particles are spherical, enveloped, and are 80-120 nm in diameter30. The viral genome is 
comprised of two copies of single-stranded, 9.7 kb positive-sense RNAs. Like all viruses 
in family Retroviridae, HIV genomic RNA encodes three canonical polyproteins: Gag, Pol, 
and Env31. The gag gene is responsible for encoding structural proteins like matrix (MA, 
p17), capsid (CA, p24)32, and a smaller nucleocapsid protein (p7), the latter aiding in viral 
genomic stability33. The pol gene encodes the reverse transcriptase (RT, p51), RNase H 
(p15), and integrase (INT, p32). The env gene is responsible for encoding the envelope 
docking (gp120) and transmembrane (gp41) glycoproteins34. Despite the limited coding 
capacity due to the relatively small size of the viral genome, alternative RNA splicing and 
overlapping reading frames allow the virus to produce six additional accessory proteins: 
Tat, Rev, Nef, Vif, Vpr, Vpu (Fig 1). These accessory proteins alter the host cell 
environment to favor viral persistence, replication, and transmission35. The host-derived 
envelope is studded with viral glycoproteins that facilitate adsorption and entry into host 
cells. These glycoproteins exist as trimeric complexes of gp41 and gp120 36.  Below the 
host-derived lipid envelope lies two proteinaceous capsids–p17 and p24–both originating 
from the Gag polyprotein. A polymeric matrix of p17, lies directly underneath the lipid 
envelope, and offers structural rigidity and integrity, whereas the viral genome is packaged 
and protected within the p2437. Multiple p7 proteins stud the viral genome. The DNA-
binding capability of p7 conferred by a basic tract of zinc-finger motifs is suggested to play 
a significant role in the affinity of p7 to RNA38.  
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Figure 1. Genomic Structure of HIV 
Three reading frames encode three canonical retroviral proteins: Gag, Pol, Env. Six 
accessory proteins are also encoded within the genome: Tat, Rev, Nef, Vif, Vpr, and Vpu. 
The genome is flanked by two long terminal repeats (LTR).  
 
Propagation of infectious HIV depends on its ability to preferentially package viral 
genomic RNA over the larger pool of existing mRNAs in the cellular milieu39.To achieve 
this, a cis-acting packaging signal (Ψ), located within the 5’ untranslated region of HIV 
RNA, facilitates binding of HIV RNA to Gag and efficiently nucleates particle formation40. 
The Ψ contains extensive secondary structure that enables the binding of multiple Gag 
molecules facilitating Gag molecule clustering and the subsequent stabilization of Gag–
Gag homotypic interactions41.  In contrast, RNA species lacking Ψ are severely limited in 
facilitating the accretion of Gag–a key requirement for nucleating virus particle 
formation39. The viral genome is flanked by regions encoding two long terminal repeats 
(LTR), which among other functions, enables the virus to integrate into the host cell 
genome as a provirus42–44. Although the LTRs contain three physical regions: U3, R, and 
U5, there are four regions that regulate transcription within the LTR. Three of these 
regulatory regions are in U3, and the remaining is in R. Each of these functional domains 
are responsible for regulating viral transcription following integration45. The 
transactivation response (TAR) element within R interacts with the HIV accessory protein, 
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Tat to promote viral mRNA production46. The basal/core promotor, core enhancer, and 
modulatory regions are found in U3 and collectively bind to a myriad of cellular 
transcription factors. Therefore, once integrated, the 5’ LTR acts as a promotor for the 
provirus and is responsible for recruiting and binding cellular transcription factors like 
nuclear factor κB (NF-κB), nuclear factor of activated T cells (NFAT), and activator 
protein 1 (AP-1), to mediate proviral transcription47. In contrast, the 3’ LTR plays less of 
a role in transcriptional initiation due to interference with 5’ LTR transcription, but rather 
aids in the polyadenylation of viral transcripts48.  
1.2.2 Mechanism of HIV Infection 
HIV has a cellular tropism for activated CD4+ T cells. This is due to the propensity of 
activated T cells to upregulate CCR5 and CXCR4, which —in concert with host CD4 
receptors and viral gp120—facilitates viral entry49,50. During the early stages of mucosal 
infection, the diverse swarm of viral quasi-species deposited within the host experiences a 
significant genetic bottleneck prior to establishing systemic infection. A study comparing 
the HIV envelope sequence diversity within the female reproductive tract and matched 
plasma samples from a cohort of acutely infected Zimbabwean and Ugandan women, 
showed disproportionate counts of distinct viral clones within the endocervix compared to 
matched plasma samples51. In particular, the viral sequence diversity within the endocervix 
was significantly higher than the sequence diversity of viral clones found in plasma. This 
suggests that the combination of physical and immunological constraints within the 
mucosa acts as a genetic sieve, resulting in the establishment of a genetically homogenous 
systemic infection (Fig 2).  
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Figure 2. Genetic sieve effect for mucosal HIV transmission 
The diverse swarm of viral quasi-species deposited into host mucosa undergoes a 
significant genetic contraction, resulting in a relatively clonal virus population that 
disseminates and establishes infection.  
 
In support of this notion, studies conducted in non-human primate (NHP) models of 
infection using atraumatic inoculation of SIV into the vaginal mucosa, have shown a single 
viral genetic variant, termed the transmitter/founder (TF) viruses, that can preferentially 
cross the epithelial barrier and establish multiple localized foci of infection within a 
population of cells52. These NHP models have also shown that 63% of early cellular targets 
for infection are CCR6+ CD4+ T cells expressing high levels of RORγT transcription factor, 
which is highly expressed in TH17 cells within the mucosa. In addition, 12% of early 
cellular targets constitute other CD4+ T cells, whereas the remaining 25% of cellular targets 
were non-T cells that were either CCR6+, corresponding to immature dendritic cells (DC), 
or non-T cells that were CCR6‒, corresponding to macrophages52. Therefore, TH17 cells 
are preferentially infected and depleted during the eclipse stages of infection in NHPs. 
Several lines of evidence suggest that TH17 cells are critical for maintaining mucosal 
barrier integrity53. Therefore, the depletion of these cells lends itself towards a reduction in 
barrier integrity, thereby encouraging viral penetration, replication, and dissemination. In 
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addition to this, there are several other mechanisms that reduce barrier integrity. For 
instance the interaction of HIV gp120 and Tat with the mucosal epithelia results in the 
disruption of epithelial tight junctions, which further deteriorates mucosal barrier 
function54–56. Substantial evidence indicates gp120 and Tat aberrantly activate mitogen-
activated protein kinase (MAPK) cascades, resulting in the deterioration of tight junction 
integrity achieved by tight junction protein internalization and proteasomal degradation57–
59.  
HIV infection is characterized by the continuous depletion of CD4+ T cells, which play an 
important role in developing adaptive immunity against pathogenic infections60. However 
as demonstrated with TH17 cells, not all CD4+ T cell subsets are depleted equally. HIV 
preferentially infects activated CD4+ T cells over their naïve counterparts61. Extensive 
studies have shown that the depletion of T cells is primarily mediated through apoptotic 
and pyroptotic mechanisms as opposed to consequences of viral cytopathic effects62. 
Furthermore, evidence suggests that majority of CD4+ T cell death occurs in uninfected 
bystander cells. Bystander cell death accounts for ~ 95% of the CD4+ T cell depletion, 
wherein viral replication is rendered abortive due to the quiescent state of these cells. As a 
result, accumulation of incomplete reverse transcripts is recognized by DNA sensor IFI16, 
resulting in caspase-1 inflammasome assembly and subsequent cell pyroptosis62. During 
pyroptosis, cytoplasmic contents and pro-inflammatory cytokines like IL-1β are released 
into the extracellular milieu, resulting in a highly inflammatory environment that attracts 
more target CD4+ T cells63. However, in the 5% of activated permissive cells, productive 
infection induces activation of caspase-3 and subsequent cell death through apoptosis. 
Therefore, it is apparent that the main driving force behind CD4+ T cell depletion is 
mediated by caspase-1 mediated pyroptosis62.  Remarkably within lymph nodes of infected 
individuals, molecular signatures of apoptosis are readily apparent in the paracortical 
zones, which is rich in resting CD4+ T cells. The ongoing pro-inflammatory environment 
imbued by apoptosis of bystander cells within this anatomical compartment contributes to 
a positive feedback loop that recruits more activated T cells and fuels CD4+ T cell 
depletion60,63,64.  
Entry into susceptible host cells require cognate recognition of viral Env with CD4, the 
latter of which is found in abundance on the cell surface of T lymphocytes. Env gp120 
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contains a CD4 binding site (CD4bs), which enables Env to interact with CD4+ T cells65. 
This binding interaction induces a localized conformational change within gp120, allowing 
binding of an entry co-receptor, either CXCR4 (X4) or CCR5 (R5). This differential co-
receptor usage gives rise to X4- or R5-tropic viruses. Once a co-receptor is bound, the 
gp120 trimer undergoes a dramatic conformational change, exposing a hydrophobic gp41 
fusion peptide that penetrates and tethers viral particles to the host cell membrane66. The 
potential energy released as a result of this conformational change drives the formation of 
a six-helix bundle that brings the viral envelope and host cell membrane in close apposition 
until a fusion pore is created, and the viral core is deposited into the cytoplasm65. The viral 
core consists of approximately 1500 monomers of p24 capsid proteins67. N-terminal 
domain interactions between capsid proteins form 250 rigid hexagonal structures that are 
linked to each other through C-terminal domain interactions. As a result of these N-
terminal domain interactions and C-terminal domain interactions, hexagonal lattice 
structures are generated, which are juxtaposed to create a unique fullerene cone. The poles 
of the cone are capped by 7 pentameric rings at the wide end, and 5 pentameric rings at the 
narrow end68. There are three models that describe the uncoating process of the viral capsid. 
In the first model, the capsid is uncoated immediately after viral capsid deposition into the 
cytoplasm. Evidence for this model suggest that virions contain high concentrations of 
capsid protein to ensure the metastability of the viral core. Capsid metastability refers to 
the equilibrium between capsid stability and instability, the former of which protects the 
genome, and the latter required for depositing viral RNA into the host cell. As a result of 
the drastic change in the concentration of free capsid protein in the cytoplasm, the core 
begins to disintegrate as the concentration of free capsid protein is too low to maintain the 
metastable integrity of the viral core69. The second model proposes that the viral core 
remains intact for some time after deposition into the cytoplasm. In this model, uncoating 
occurs gradually as the viral core is trafficked towards the nucleus and reverse transcription 
is initiated. This model hypothesizes that as the core is transported to the nucleus, several 
conformational rearrangements within the capsid protein trigger uncoating. Evidence 
suggests that these molecular rearrangements are induced by three independent factors: 
changes in the colligative properties of intracellular milieus between different intracellular 
compartments, interaction with various cellular factors, and molecular rearrangements that 
accompany reverse transcription70. In support of this model, it has been shown that viral 
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cores in the cytoplasm attain different sizes and shapes compared to mature extracellular 
cores. The broad morphological spectrum encompassed by viral cores within the cell is 
thought to correspond to complex molecular transformations as the core is transported to 
the nucleus71. However, these morphological changes may be accounted for by variations 
in preparation and isolation protocols and therefore, must be taken into consideration. The 
third, and most popular model, predicts a late uncoating event since reverse transcriptase 
is maintained at a high stoichiometric ratio to the viral genome within the core, which 
offsets the tendency of reverse transcriptase to dissociate from its template. This model 
suggests late uncoating because the dilution of reverse transcriptase in the cytoplasm would 
reduce the stoichiometric ratio of reverse transcriptase to its template, resulting in 
inefficient reverse transcription70,72. Inter-ring spaces within the viral core are 10 nm in 
size and permits the entry of non-limiting deoxyribonucleotides within the cytoplasm into 
the viral core, facilitating reverse transcription. 
Like other DNA polymerases, reverse transcriptase requires a primer and template to 
initiate polymerization. A host-derived tRNA, usually Lys3, captured within the viral core 
during particle synthesis mediates priming for reverse transcriptase73. The tRNA binds to 
a 5’ region, 182 bp downstream of the 5’ end of the RNA genome, called primer binding 
site (PBS), which enables the initiation of reverse transcription. Reverse transcriptase 
catalyzes DNA synthesis and reaches the 5’ end of the genome after synthesizing a minus-
strand strong stop cDNA ((–) ssDNA), which is 181 bp in length. Concomitantly, RNase 
H, which is a catalytic domain within reverse transcriptase, degrades viral RNA in the 
context of RNA-DNA duplexes. In a subsequent (–) ssDNA strand transfer event, the (–) 
ssDNA dissociates and interacts with the 3’ end of the LTR through complementary base-
pairing. Two polypurine tracts (PTT) within the viral RNA – namely the central PPT 
(cPPT) and 3’ PPT – resist degradation by RNase H and serve as primers for plus (+)-
strand synthesis. This is a unique property of viruses within genus Lentiviridae in that (+)-
strand DNA synthesis is primed at two independent locations within the viral genomic 
RNA. That is, the primary upstream site of extension is primed by Lys3 tRNA binding to 
PBS, whereas the secondary downstream site of extension is primed by the 3’ PPT. As a 
result of this phenomenon, as the downstream (+)-strand DNA is displaced by upstream 
(+)-strand DNA during strand displacement synthesis, a central DNA flap that is 99-
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nucleotides long is generated. Importantly, several studies show the importance of the 
central DNA flap as a cis-determinant for core disassembly and nuclear import. In support 
of this, several studies show that inhibiting reverse transcription or abrogating central DNA 
flap formation, leads to an accumulation of viral cores at the nuclear membrane that contain 
the viral genome. This suggests that viral core uncoating is dependent on the completion 
of reverse transcription and offers evidence that challenge the notion of progressive viral 
core uncoating70. Therefore, uncoating is not triggered until reverse transcription is 
completed, and the viral core has trafficked to the nuclear pore. Once this occurs, several 
cellular and viral proteins interact with the dsDNA molecule to form the karyophilic pre-
integration complex (PIC), capable of facilitating the transport of the viral genome into the 
nucleus (Fig 3). Although capsid protein is not detected in the PIC, the presence of other 
viral proteins such as MA is a subject of contention. However, it is known these PICs 
contain virally encoded INT and host-derived proteins that facilitate the import of the PIC 
into the nucleus in an energy-dependent manner74. Viral CA interacts with host RANBP2 
to facilitate docking of the viral core to the cytoplasmic face of nuclear pore complex, 
which further supports the hypothesis that viral uncoating is not triggered until the viral 
core has trafficked to the nuclear pore75. Virally encoded Vpr contains a non-canonical 
nuclear localization signal (NLS), allowing the import of Vpr into the nucleus through 
importin-α-dependent pathways. Here, Vpr interacts with nucleoporins within the 
nucleoplasmic face of the nuclear pore complex, such as NUP153, to facilitate viral core 
binding. 
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Figure 3. Nuclear import of HIV PIC through nuclear pore complexes 
The HIV PIC is imported into the nucleus in a manner dependent on both cellular and viral 
proteins. Once in the nucleus, the PIC mediates proviral integration into host genome.    
 
In addition, host cleavage and polyadenylation specificity factor 6 (CPSF6) has been shown 
to interact with viral CA protein, and import RNA splicing machinery into the nucleus76,77. 
Importantly, CPSF6 plays a critical role in targeting viral integration into highly expressed 
genes within open chromatin (euchromatin) areas of the chromosomes. In loss-of-function 
studies, that mutate the viral CA protein to diminish its binding affinity for CPSF6, the PIC 
enters the nucleus through alternative mechanisms that are not well characterized and 
integrates into transcriptionally repressed regions of chromatin. In fact, this mutant has 
been shown to become insensitive to knockdowns in RANBP2 and NUP153. Therefore, it 
is suggested that CPSF6 promote entry of the PIC into the nucleus through import 
mechanisms that rely on RANBP2 and NUP153 and plays an important role in targeting 
the integration of viral genomes into euchromatin.  
Once the PIC enters the nucleus, for reasons that are not clear, over 85% of PICs are 
believed to not integrate into the host genome78. Due to the inverted LTRs, the viral DNA 
can auto-integrate and produce a variety of circular structures. In addition, host double-
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strand break repair systems, such as nonhomologous end-joining, detects the dsDNA and 
generates 2’ LTR circles to decrease the amount of free DNA ends within the cell, which 
in turn subverts cellular apoptotic responses to double-stranded breaks79,80. In the 
remaining cases, the viral DNA successfully integrates into the host genome as a provirus. 
In all cases, INT is responsible for catalyzing two important reactions: 3’-end processing 
and strand transfer events. The former reaction involves the removal of two nucleotides on 
the 3’ ends of the dsDNA viral genome to generate reactive 3’ hydroxyl ends that are 
biochemically primed for integration into the host genome. During strand transfer, 
integrase uses the 3’-hydroxyl groups to nucleophilically attack a 5’-α-phosphate in the 
major groove of host DNA, while the D,D(35)E motif within integrase, comprised of three 
evolutionarily conserved amino acid residues (Asp64, Asp116, and Glu152), chelates two 
Mg+2 ions to mitigate unfavorable charge interactions between host DNA and viral DNA 
during nucleophilic attack81. Following this, single-stranded gaps created during 
integration are repaired using host DNA repair machinery.  
Integration, is not a random process. It favors transcriptionally active genes82,83. Integration 
site analyses within infected individuals have shown HIV integration into highly 
transcribed genes, especially those encoding transcriptional regulator protein (BACH2), 
myocardin-like protein 2 (MLK2), and signal transducer and activator of transcription 5B 
(STAT5B)84,85. Interestingly, all three genes correspond to cellular growth factors, whereas 
BACH2 and MLK2 are reported to have proto-oncogenic functions. High levels of viral 
integration have also been shown to correlate with genes that have specific histone marks. 
Specifically, acetylation of histone H3 lysine at position 9 (H3K9ac) and trimethylation of 
histone H3 lysine at position 36 (H3K36me3), have been shown to be associated with 
highly transcribed genes, and are often correlated with sites of viral integration, supporting 
the notion that HIV preferentially integrates into highly transcribed regions of the genome. 
Host lens epithelium-derived growth factor (LEDGF) binds to integrase through its C-
terminal integrase-binding domain (IBD), while the N-terminal Pro-Trp-Trp-Pro (PWWP) 
domain binds H3K36me3, effectively tethering integrase to euchromatin. In fact, depletion 
of LEDGF results in a drastic shift of integration away from actively transcribed genes86–
89. Although both CPSF6 and LEDGF play significant roles in targeting the viral genome 
into euchromatin, tandem knockout studies reveal that CPSF6 is more dominant in 
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euchromatin targeting activity; however, a reduction in either CPSF6 or LEDGF 
expression can shift integration into heterochromatic regions of the genome89. Therefore, 
a two-phase mechanism that involves both LEDGF and CPSF6 is most probable. It is 
suggested that CPSF6 binding to capsid protein docked to the nuclear pore complex is a 
prerequisite for directing integrase-LEDGF to euchromatin. Spatially, integration 
preferentially occurs in genes located near the periphery of the nucleus, underlying the 
nuclear pore complex90. Genes located within the center of the genome that are highly 
repressed through heterochromatinization are highly disfavored for integration. To this 
effect, in situ hybridization by 3D immunofluorescence corroborates this phenomenon as 
HIV integration sites are consistently found within euchromatin structures that are 1 µm 
away from the nuclear periphery and the nuclear pore complex91. Taken together, regions 
of euchromatin found under nuclear pore complexes near the nuclear periphery will be the 
preferred sites of integration and viral expression. Transcription of the provirus results in 
transcripts that are either exported as unspliced RNA for packaging into virions, or 
extensively spliced and exported from the nucleus to produce viral transcripts and generate 
viral particles92. A schematic overview of the HIV replication cycle is described in Figure 
4.  
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Viral fusion is triggered by gp120 interaction with CD4 and co-receptor CCR5/CXCR4. 
Upon entry, viral uncoating and reverse transcription occur before the viral genome is 
imported into the nucleus and integrated into host chromosome. Proviral transcripts are 
exported from the nucleus and are used for translating HIV proteins. These proteins self-
assembled 
 
1.2.3 Immunology of HIV Infection 
Once the virus disseminates from the mucosa to local draining lymph nodes, an 
evolutionary arms race between the host immune system and the TF virus ensues. Due to 
a combination of factors stemming from the lack of RT proofreading mechanisms, high 
frequency of viral recombination, and host APOBEC3-mediated substitutions of the viral 
genome, viral diversity greatly expands. Additionally, during acute stages of infection, 
cytotoxic T lymphocyte (CTL) responses place a positive selection pressure on the virus, 
fueling the evolution of CTL escape mutants. Most escape mutations occur within viral 
epitopes that are recognized by T cells. Viral escape is further maintained, through the 
concerted actions of HIV Nef-mediated downregulation of HLA-A, B, and C on infected 
CD4+ T cells93. Because the virus preferentially infects activated T cells, the persistent viral 
replication ongoing within lymph nodes only accelerate the apoptotic death of responding 
CD4+ T cells while pyroptosis decimates T cells expressing TCRs of non-HIV specificities 
94. As a result, systemic T cell counts gradually decline.  The virus eventually disseminates 
into the gut-associated lymphoid tissue (GALT)–an anatomical site rich in T and B 
lymphocytes. Permissive CD4+ T cells fuel the rapid explosion of virus propagation within 
the lamina propria of the GALT. CD4+ T cell counts subsequently plummet as a result of 
cell death associated with viral cytopathic effects (vCPE) and pyroptosis of uninfected 
bystander cells94. In the absence of prompt medical intervention, individuals experience 
acute HIV syndrome within 3-6 weeks, characterized by high plasma viremia as the 
immune system deploys humoral and cellular-mediated responses to counteract the 
infection95. However, the immune response is unable to resolve the infection, and HIV 
continues replicating in CD4 T cells and within primary and secondary lymphoid tissues. 
Figure 4. Schematic Overview of HIV Replication Cycle 
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Following peak viremia, the contraction phase of infection begins and is marked by the rise 
of CD8 CTLs and viral escape mutants. The viral loads continue to decline until a viral set 
point is reached, which is then maintained until such time as the immune system is 
completely degraded and the infected individual progresses towards AIDS. Over the course 
of infection, excessive antigen exposure and continual stimulation of CD8+ and CD4+ T 
cells promotes functional exhaustion of both populations of T cells. Evidence suggests 
these exhausted T cells express high levels of inhibitory receptors, such as PD-1, Tim-3, 
and CTLA-4, resulting in severely compromised adaptive anti-viral responses96–98. In 
addition to weakening a critical cellular component of the immune response through the 
combined efforts of CTL escape, CD4+ T lymphocytopenia and T cell exhaustion, HIV 
induces the immunological dysfunction of other immune cells99. For example, 
hypergammaglobulinemia induced by clonal B cell expansion, Ig class switching, and 
differentiation are readily found within HIV-infected individuals100,101. Lymph nodes 
contain B cell follicles, where IgM+ IgD+ B cells reside and are superficially separated from 
the subcapsular sinus by the interfollicular zone. During adaptive immune responses, the 
B cell follicle cultivates the formation of a germinal center, at the center of which lies a 
network of follicular dendritic cells (FDC) responsible for promoting B cell survival. 
Underlying these structures and bordering each B cell follicle is the T cell zone, which as 
the name suggests, consists of T cells but also contains DCs.  There is evidence suggesting 
that these FDCs can present virus to naïve B cells through long-lived complement receptor-
mediated structures called iccosomes102,103. The resulting B cell receptor cross-linking, 
antigen internalization, and presentation on MHC II allows the B cell to migrate to the 
border of the B cell and T cell zones. Here, follicular T helper (TFH) cells provide the 
necessary cognate interactions and co-stimulatory signals to induce 
hypergammaglobulinemia through B cell clonal expansion, Ig class switching, and 
differentiation. The sustained deterioration of the immune system often clinically manifests 
as an acquired immunodeficiency syndrome (AIDS)-defining illness. Individuals at this 
stage of infection are severely immunocompromised and have poor prognoses due to their 
inundation with opportunistic infections and/or cancer104.   
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1.3 Antiretroviral Therapy  
In the early 1990s, inhibitors for reverse transcriptase, such as Zidovudine and Didanosine 
were used extensively as monotherapies. Interestingly, Zidovudine was the first 
antiretroviral therapy approved for use against HIV. These nucleoside analog reverse-
transcriptase inhibitors (NRTI) compete with cellular deoxynucleotides for incorporation 
into the growing strand of DNA produced by reverse transcriptase. However, the NRTI 
does not contain a 3’-hydroxyl group that can be further elongated, resulting in a premature 
chain termination event. Due to the high viral turnover rates and large viral population size 
during acute stages of infection, the propensity of resistant mutants appearing after single 
therapy is much higher compared to the use of combination therapies. Therefore, during 
the mid-1990s, the standard of care evolved to include dual therapy treatment regimens, 
which usually included a reverse transcriptase inhibitor and a protease inhibitor. The latter 
of which suppresses the production of infectious virions by inhibiting proteolysis of viral 
polyproteins. Interestingly, mathematical modelling suggested a minimum of three 
mutually independent mutations must be established to subvert a durable inhibition of HIV 
replication under combination therapy105. Therefore, in the late 1990s, combined anti-
retroviral therapy (cART) was introduced by leveraging three or more different 
antiretroviral drugs, targeting several targets of viral replication, to effectively mitigate the 
chances of accruing viral resistance. These additional classes of antiretroviral drugs 
included non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase inhibitors, 
fusion inhibitors, and co-receptor antagonists.  
To date, cART is the only effective treatment for individuals infected with HIV, and 
effectively prevents progression to AIDS106. Many infected people are unaware of their 
HIV status107. Of those that are aware, a significant proportion often have immense 
difficulty in accessing cART due to various social and economic constraints108. Despite the 
countless lives that have been saved by this therapy, without a curative approach to 
eradicate the disease, HIV infection remains a significant healthcare burden due to its 
manifestation as a life-long treatment-manageable, chronic infection. If cART is 
interrupted, rapid viral rebound occurs within days. This is suggestive of a discrete 
population of latently infected cells harboring replication-competent provirus that is 
rapidly reactivated when the suppressive actions of cART are removed. It therefore follows 
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that cART is unable to facilitate a sterilizing cure due to replication-competent HIV that 
persists despite antiretroviral therapy.   
1.4 The Latent Reservoir 
1.4.1 How the Latent Reservoir is Established  
Studies characterizing the latent reservoir have provided evidence suggesting that latency 
is “hardwired” into the HIV genome through a gene-regulatory circuit that maximizes 
transmission by minimizing viral extinction109,110. The most well-characterized repository 
for these replication-competent proviruses are within a mono- or oligoclonal population of 
resting memory CD4+ T cells, termed the latent reservoir. Other characterization studies in 
resting CD4+ T cells that comprise majority of the latent reservoir have shown that dNTP 
levels are 10- to 100-fold lower than their activated counterparts, which in concert with 
other mechanisms, effectively “traps” the HIV provirus and contributes to the maintenance 
of the latent reservoir111–113.   
 
During infection of activated T cells, the viral infection is often productive and results in 
Caspase-3 activation and rapid apoptotic cell death114. However, within a very small 
proportion of activated T cells, viral integration as a provirus can occur concomitantly with 
the transition of the T cell into a memory phenotype. As cells transition into resting memory 
T cells, the cell cycle enters G0, characterized by a low metabolic state. The transition into 
G0 is marked by repression of transcriptional machinery to facilitate cellular quiescence.  
Cellular levels of NF-κB, AP-1, NFAT are significantly downregulated upon entry into G0, 
and therefore cannot facilitate transcription from the 5’ LTR. Moreover, in quiescent cells, 
the cyclin T1 (CycT1) subunit of the positive transcription elongation factor b (P-TEFb) is 
rapidly degraded. This silences all transcriptional initiation as P-TEFb is sequestered and 
inactivated within 7SK small nuclear ribonucleoprotein (snRNP) complexes that contain 
hexamethylene bis-acetamide-inducible (HEXIM) 1/2 repressor proteins. Furthermore, 
several epigenetic mechanisms ensure proviral latency is maintained. Regardless of the 
location of proviral integration, two nucleosomes (Nuc-0 and Nuc-1) position themselves 
on the 5’ LTR. Modification of histones within Nuc-0 and Nuc-1 through histone 
deacetylases (HDAC) and histone methyltransferases (HMT) result in heterochromatic 
silencing. The resulting heterochromatic structure also induces RNA polymerase II 
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promotor-proximal pausing, resulting in inefficient proviral transcription during latency115. 
In fact, in latently infected cells, up to 3% of chromatin-associated RNA polymerase II can 
be found paused proximal to promotors within the 5’ LTR. In addition to promotor-
proximal pausing, proviral transcription is impeded by its abortive nature during latency 
because of low Tat availability. This is because low Tat in latently infected cells induces 
premature termination of any elongating RNA polymerase II. This is achieved by the 
recruitment of the negative elongation factor (NELF) through DRB sensitivity-inducing 
factor (DSIF), which recognizes nascent RNA emerging from RNA polymerase II116. It 
therefore becomes apparent that the state of viral latency is sensitive to the availability of 
Tat. In fact, there are two transcriptional circuits that are activated based on Tat 
availability117. When high levels of viral Tat are available, a complete transcriptional 
circuit is established wherein Tat production outcompetes NF-κB binding to CDK9, 
enabling hyperphosphorylation of the C-terminal domain of RNA polymerase III, which 
further increases transcriptional activation of the provirus. In contrast, when low levels of 
viral Tat are available, an incomplete transcriptional circuit is established because Tat 
levels are too low to outcompete NF-κB binding to CDK9. As a result, only a basal level 
of transcriptional activation is initiated118,119. Taken together, these are some of the 
mechanisms that promote the transcriptional pausing of proviral genes, effectively trapping 
the HIV provirus within the cell and seeding the latent reservoir120.  
Despite these restrictions, replication-competent proviruses within the latent reservoir 
retain the capacity to reignite viral replication upon T cell receptor stimulation and/or 
cytokine-mediated activation121–123. Following T cell receptor stimulation of latently 
infected cells, a signaling cascade is initiated, mobilizing NFAT and NF-κB into the 
nucleus. These proteins subsequently recruit histone acetyltransferase (HAT) complexes 
such as CBP/p300, that remove heterochromatic silencing induced by HDACs or HMTs 
and allow for euchromatic proviral expression. As transcripts are being produced, Tat 
levels within the cell correspondingly increases through a positive-feedback loop, 
characteristic of a complete transcriptional circuit. This is because Tat binds strongly to 
P-TEFb, which is displaced from the repressive 7SK snRNP complex upon Tat binding. 
The Tat-P-TEFb complex subsequently recruits the super-elongation complex (SEC), 
which activates productive RNA polymerase II elongation complexes. This conversion of 
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RNA polymerase II from a promotor-proximal paused state into a processive state 
requires promotor clearance. This is mediated by phosphorylation of the C-terminal 
domain of RNA polymerase II, which is catalyzed by CDK9 and the kinase activity of the 
Tat-P-TEFb complex.  
Evidence supporting the existence of the latent reservoir can be gleaned from studies 
characterizing viral kinetics during cART administration. The primary drastic reduction of 
plasma viremia upon cART initiation often underscores a secondary slower decay of 
viremia. The slower decay kinetics reflect a slow cell turnover rate that deviates 
significantly from the short turnover of productively infected cells. Upon further 
characterization, the slow decay kinetics were found to be associated with latently infected 
memory CD45RO+, HLA-DR– CD4+ T cells124. The intrinsically long-lived property of 
this cell population, combined with stem cell-like regenerative capabilities imbued by 
homeostatic proliferation, results in a persistent latent reservoir harboring provirus. There 
are seven main families of resting memory CD4 T cells, each of which show differential 
permissivity towards latent HIV infection. In particular, the long-lived central memory T 
cells (TCM) are most permissive and contain the highest proportion of cells that are latently 
infected, whereas shorter-lived populations such as transitional memory (TTM) and 
effector memory (TEM) T cell populations contain less125. Although the cellular 
composition of the latent reservoir remains relatively similar between chronically infected 
and acutely infected individuals, the size of the latent reservoir in acutely infected 
individuals is significantly smaller than those found in chronically infected individuals. 
This phenomenon is heavily influenced on the timing of cART, with early antiretroviral 
intervention significantly limiting the amount of cells harboring HIV DNA125,126. 
Several longitudinal evolutionary studies of HIV Env diversity following cART 
interruption have provided evidence that the latent reservoir is seeded during very early 
stages of infection. In one such study, 46 chronically infected patients were subjected to 
multiple two-week structured treatment interruptions. Env was sequenced from the 
resulting swarm of rebound virus, and was found to be highly homogenous, which is 
consistent with a virus of monoclonal or oligoclonal origin and is genetically reminiscent 
of early TF strains127. Importantly, evidence from SIV infection in rhesus monkeys have 
elucidated details that uncover the influence of time until cART initiation, on the 
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characteristics of the latent reservoir. In one such study, rhesus monkeys were distributed 
among four experimental groups corresponding to increasing time of cART intervention 
following intrarectal SIV challenge (3 days, 7 days, 10 days, 14 days). There was an 
apparent inverse correlation between the time taken to administer cART following 
exposure, and the time it takes to experience viral rebound. In fact, monkeys that were 
administered cART 3 days post-SIV challenge displayed threefold delayed kinetics 
compared to monkeys administered cART 14 days post-challenge52. These findings 
corroborate details found within the interesting “Mississippi Baby” case who acquired the 
infection in utero. In 2010, a baby girl–popularized as “The Mississippi Baby”–was born 
to a mother who was found to be HIV+ only during labor due to lack of prenatal care. As a 
result, the normal standard of care of administering cART prior to childbirth could not be 
achieved, which would have in retrospect, prevented vertical transmission of HIV to the 
baby. As expected, soon after birth, the Mississippi Child was determined to be HIV+ and 
was treated with an aggressive course of cART within 30 hours of her birth. The 
Mississippi baby tested positive for HIV at 6, 11, and 19 days old; however, when the 
Mississippi Baby was 29 days old, HIV RNA copies decreased below detectable levels (< 
20 copies per mL). When she was 18 months old, the mother reported that she had stopped 
administering cART to the baby. Remarkably, after a year of cART cessation, viral RNA 
copies were still undetectable in blood. However, when the girl became 4 years old, she 
experienced a significant viral rebound, which resulted in viremia present at 10,000 
copies/mL. Until the initiation of the viral rebound, she had been – for all intents and 
purposes –functionally cured, since her viral titers had remained below detectable levels. 
The case of The Mississippi child illustrates that despite early cART intervention, the latent 
reservoir is seeded extremely rapidly. In support of this idea, cART initiation during later 
stages of infection results in a higher proportion of resting memory CD4+ T cells harboring 
provirus containing CTL escape mutations. This is reflective of the predominance of CTL 
escape mutants during later stages of infection. In contrast, when cART is administered 
during very early stages of infection, CTL responses are not fully developed, and adaptive 
immune responses have not been mobilized. Correspondingly, the latent reservoir from 
these individuals is limited in size and proviruses do not contain CTL escape mutations128.   
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In the absence of cART intervention, a single latently infected T cell that is stochastically 
activated has the potential of producing viral particles that can infect other T cells. This 
rebounding virus can result in an explosion of virus production. In fact, there is substantial 
evidence in humans and in non-human primate models of infection, describing that viremia 
can be detected within days to weeks of cART cessation129. In fact, the latent reservoir is 
thought to be very stable and if solely relying on cART and stochastically reactivating 
virus, the latent reservoir would require >70 years of continuous cART in order for it to 
decay to the extent that a cure could be realized. Therefore, continual, unabated cART, is 
unlikely to constitute a cure on its own. This highlights the importance of developing 
additional curative interventions against HIV through the eradication of the latent reservoir.   
1.4.2 Approaches for Eradicating the Latent Reservoir  
Studies investigating the control of HIV latency have been seminal in understanding 
mechanistic approaches to eradicate the latent reservoir. However, the accuracy of these 
studies is greatly hindered by the low frequency of latently infected cells in vivo. Therefore, 
the use of various cell lines to model and quantify latency have been highly advantageous. 
However, these in vitro models cannot fully recapitulate the physiological conditions of a 
quiescent G0 cell state. Apart from the Verdin model of latency, which uses Jurkat-derived 
T cell clones, all models utilize primary CD4+ T cells that are spinoculated with either 
GFP-based or luciferase-based HIV reporter constructs. However, only results obtained by 
the quantitative viral outgrowth assay (QVOA) offer the most accurate representation of 
latency. This is because QVOA estimations of reservoir size measure frequency of 
endogenous provirus within primary cells, whereas other estimations use cell lines. Since 
cART is unable to eradicate the latent reservoir within a reasonable timeframe, alternative 
approaches to purposefully activate latently infected cells are being investigated. The HIV 
cure field has rallied around the “shock and kill” approach to eradicating the latent 
reservoir130,131. This approach uses T cell activating agents, termed latency reversal agents 
(LRA), designed to reactivate latently infected T cells. In doing so, the cell cycle exits G0, 
and the pool of transcription factors increases. Subsequent virus transcription can be 
initiated by transcription factor binding of proviral 5’ LTR and induce virion production. 
This process of forcing the virus out of hiding, constitutes the “shock” aspect of the 
approach. As soon as latently infected cells begin to produce virus, they are exposed to a 
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combination of immune-mediated and/or viral cytopathic-mediated destruction, 
constituting the “kill” aspect of the approach. The foundation of this strategy is the 
simultaneous delivery of LRA and cART, which respectively function to accelerate the 
decay of the latent reservoir and inhibit de novo infection of healthy CD4+ T cells. Early 
LRAs attempted to induce latency reversal via global T cell activation. Here, combinations 
of IL-2 and anti-CD3 antibodies were screened for latency reversal potential 132,133. An 
alternative strategy was also explored, which involved protein kinase C (PKC) agonism 
using synthetic or naturally occurring ingenol compounds. These compounds are molecular 
mimics of diacylglycerol (DAG), which activate PKC. Activated PKC is capable of 
sequestering inhibitory IκB and would free NF-κB to bind the proviral 5’ LTR and activate 
transcription134,135. One of the more promising pharmacological LRAs have been the class 
of histone deacetylase inhibitors (HDACi), which include compounds such as vorinostat, 
panabinostat, and romidepsin. A component of proviral latency relies on the epigenetic 
repression of transcription through localized heterochromatization, mediated by histone 
acetylation. Therefore, inhibition of enzymes responsible for catalyzing the acetylation 
reaction may induce euchromatinization, which would in turn promote proviral 
transcription. Another class of LRAs are the bromodomain and extra-terminal domain 
inhibitors (BETi), such as JQ1. These molecules activate P-TEFb signaling by inhibiting 
bromodomain-containing protein 4 (BRD4). Since BRD4 competes with Tat for binding 
P-TEFb, inhibiting BRD4 increases the proportion of P-TEFb bound by Tat, which can 
subsequently initiate proviral transcription.  
The latency reversal capabilities of toll-like receptor (TLR) agonists have also recently 
been explored. In addition to other pattern recognition receptors (PRR), TLRs are sentinel 
receptors of the innate immune system that detect pathogen-associated molecular patterns 
(PAMP) and activates immune signaling cascades to mount an appropriate counter-
response. Several studies have shown that this counter-response is strong enough to 
reactivate resting CD4+ T cells. For example, a TLR1/2 agonist PAM3CSK4 has been 
shown to induce viral reactivation from a cultured population of central memory T cells 
isolated from five aviremic individuals136. Flagellin, a TLR5 agonist, has been shown to 
induce latency reversal in J-lat and Jurkat latently infected cell lines, and central memory 
T cells isolated from two aviremic individuals137. TLR3 activation using poly(I:C) has been 
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shown to induce latency reversal in the HC69 cell line, which are immortalized microglial 
cells138. MGN1703 is a synthetic TLR9 agonist currently in phase 3 clinical trials for the 
treatment of metastatic colorectal cancer. This compound was shown to enhance both 
proviral transcription and NK-mediated killing of latently infected cells139. TLR7/8 
agonists like GS-9620 and imiquimod have shown to reduce the size of the latent reservoir 
in SIV-infected rhesus macaques, and enabled two of nine animals to remain aviremic for 
two years after cART cessation140. These TLR7/8 agonists induce the production of T1 
IFNs and other antimicrobial countermeasures (Fig 5). Although the these LRAs are 
capable of inducing detectable latency reversal, they fail to consistently reduce the overall 
size of the latent reservoir, measured by QVOA models of latency reversal141–143. 
Importantly, due to the promiscuity of these LRAs, these strategies may correlate with 
significant side-effects associated with massive cytokine release144 induced by widespread 
T cell activation. Unlike TLR7/8 agonists, other non-specific LRA are unable to stimulate 
IFN responses, which precludes clearance of the latent reservoir mediated by anti-viral 
effects145. In particular, the use of HDACi as an LRA is a double-edged sword, as this class 
of molecules has been associated with inhibition of cytotoxic T cell responses, which 
would ultimately undermine the “kill” arm of the “shock and kill” strategy146. It therefore 
follows that latency reversal should be a more targeted approach. 
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Figure 5. Detection of Virally Packaged RNA through Endosomal TLR7/8 
Virally packaged RNA induces dimerization of TLR7 or TLR8, which allows recruitment 
of MyD88 to the Toll/IL-1R (TIR) domain of TLR7/8. This enables an adaptor protein 
MyD88 to bind and activate IRAK4/TRAF6, which activates a complex of 
TRAF3/IRAK1/IKKα resulting in the phosphorylation of IRF7 and its translocation into 
nucleus. Here, IRF7 enables the transcription of type I IFN genes. In addition, the 
MyD88/IRAK4/TRAF6 complex ubiquitinates NEMO and TAB proteins resulting in the 
activation of TAK1. Subsequently, activated TAK1 phosphorylates IκB kinase (IKK) 
complex, enabling the phosphorylation of the inhibitory IκB subunit of NF-κB. This 
enables NF-κB translocation into the nucleus where it stimulates genes responsible for 
enacting antimicrobial countermeasures such as defensins, iNOS, and TNFα.   
 
1.4.3 Targeted Reactivation of the Latent Reservoir  
Targeting the latent reservoir requires identifying cells that harbor provirus; however, this 
task has been a major stumbling block for cure research. Recent advances have suggested 
several markers may be characteristic of latently infected cells. This includes CD32a, 
whose expression has been reported to be high within T cells that are latently infected, 
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whereas bystander cells showed little to no detectable expression147. This phenomenon 
suggests some mechanism of latency may be involved in the upregulation of CD32a. 
However, conflicting evidence showing no enrichment of HIV-1 DNA from CD32a+ CD4 
T cells suggest that this phenomenon may be an artifact of adherent non-T cells bearing 
this marker148. 
However, there are three lines of evidence suggesting that the latent reservoir is mostly 
comprised of memory T cells with T cell receptor (TCR) specificities towards HIV 
antigens. In a study by Demoustier et al., the antigen specificity of purified CD4+ T cells 
from five aviremic HIV infected individuals on cART were characterized by activating 
cells with either HIV-derived antigens or other common antigens (e.g. tuberculin purified 
protein derivative, peptides from cytomegalovirus)149. Based on the proportion of activated 
T cells in response to HIV-derived proteins, relative to T cells activated in response to 
common antigens, the pool of HIV-specific T cells was estimated to be 5- to 100-fold 
greater than T cells with alternative antigenic specificities149. Secondly, in a study by 
Douek et al., more proviral HIV DNA was found within memory CD4+ T cells that were 
HIV-specific compared to CMV-specific memory CD4+ T cells150. Thirdly, HIV latency 
reversal has been shown to be induced using HIV-derived peptides151–153. Hence, our group 
previously hypothesized that the direct TCR stimulation of latently infected T cells using 
HIV-derived antigens, that covers a diverse repertoire of HIV-specific TCR epitopes, may 
maximally trigger the latent reservoir into transcriptional activity i.e. shock the virus. Since 
we, and others, hypothesize that a significant proportion of the latent reservoir consists of 
CD4+ T cells expressing HIV-specific TCRs, our group’s initial effort was focused on 
targeting HIV-specific T cells for reactivation. To do this we first engineered an HIV-
derived virus-like particles (VLP) vaccine formulation, based on the quasi-species found 
in HIV subtype B infected individuals who were diagnosed and treated at the chronic stage 
of infection. The use of VLPs as both an antigen delivery and latency reversal platform 
were highly attractive for our research for several reasons. These non-infectious ordered 
arrays of genomeless, self-assembling viral proteins, mimic native virion structure154 are 
antigenic, noninfectious and easy to produce. Furthermore, VLPs – despite being a 
relatively new technology – have garnered great success at translating to clinical 
application. For instance, the high protection efficacy of Gardasil®–a Human 
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Papillomavirus (HPV) VLP– and RECOMBIVAX®– a Hepatitis B VLP formulation are 
both commonly administered today and offer some of the highest levels of protection of 
any vaccine, in this case against Hepatitis B and different strains of HPV 155. Another 
attractive property of VLP vaccines is their particulate structure, allowing them to be 
efficiently internalized and processed by antigen-presenting cells (APC), which we 
believed to be advantageous in terms of APC presentation to CD4 T cells. Finally, VLP-
based vaccines are capable of inducing strong humoral responses due to their polyvalent 
nature, and ability to efficiently crosslink B-cell receptors and activate B cells.     
Our initial studies using the VLPs to trigger proviral transcriptional activity demonstrated 
that the VLPs were efficient latency reversal agents. In fact, the VLPs were able to induce 
more HIV latency reversal than all clinically relevant LRAs tested, including HDACi and 
PKC agonists (manuscript submitted). To demonstrate specificity of the targeting, we 
compared latency reversal induced by VLPs against other antigens such as common recall 
antigens (i.e. Flu M1 peptide pool, tetanus toxoid protein, CMV peptide pools, Ebola 
(EBV) gp42 protein) and against other viral particle formulations such as feline 
immunodeficiency virus (FIV) VLPs and simian immunodeficiency virus (SIV) VLPs. 
Latency reversal was determined using an ex vivo DC-T cell co-culture assay and optimized 
qRT-PCR assay. The results consistently showed that HIV antigens cause greater latency 
reversal compared to other immunostimulatory antigens.  
The advantage of HIV VLPs over other immunostimulatory formulations lies in its 
capacity to deliver a diverse array of HIV proteins and therefore activate a diverse range 
of CD4 T cells specific against HIV peptides. The diversity contained in the VLP-based 
LRA vaccine, should in theory, enable the vaccine to have a more global application, 
although this would need to be tested in blood samples derived from individuals presenting 
with differing subtypes of HIV infection. Previous studies exploring HIV cure used 
dendritic cell-based vaccines designed to elicit antiviral T cell responses for invoking anti-
viral CTL responses. These studies involved DC-mediated presentation of autologous virus 
or viral peptides for targeted reactivation of the latent reservoir in both humans and in the 
rhesus macaque-SIV model. To this extent, a study that vaccinated macaques with 
chemically inactivated SIV-pulsed DCs showed an effective and durable SIV-specific 
humoral and cellular immunity. Over the course of the study (34 weeks) these animals 
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sustained a 50-fold decrease of SIV DNA and a 1000-fold decrease in SIV RNA found in 
peripheral blood156. In a similar study, a therapeutic DC-based treatment with autologous 
aldrithiol-inactivated HIV-1 resulted in a 80% decrease in median viral loads over 112 days 
following immunization157. These studies attributed the DC-mediated presentation of HIV 
antigens to effectuating a CTL-mediated control. However, to our knowledge, our group is 
the first to provide evidence suggesting that the decline in latent reservoir size using DC 
presentation of HIV antigens, may not be associated with CTL control. Rather, it may be 
due to a “shock” effect which induces transcriptional reactivation of the provirus 
(manuscript under review).  
1.5  Hypothesis, Rationale, and Objectives 
Initial characterization studies with HIV VLPs revealed that they were less antigenic than 
a related viral particle (VP) formulation containing packaged HIV RNA. Interestingly, the 
only difference between the VP and VLP formulations is: the presence or absence of 
packaged HIV RNA. This observation raised several lines of questioning (Fig 5): whether 
virally packaged RNA in VPs increases virion antigenicity by its intracellular recognition 
by PRRs; whether changes in antigenicity are correlated to changes in latency reversal 
potency; and if the prior two hypotheses are true, whether a heterochthonous packaging-
competent RNA containing immunostimulatory motifs could replace HIV RNA and 
augment VLP antigenicity and latency reversal. To address these questions, we established 
three main objectives: 
1. Determine whether TLR stimulation can enhance HIV VLP-mediated latency 
reversal. 
2. Characterize the relative antigenic contribution of packaged HIV RNA in VPs, 
and the impact this has on latency reversal.  
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3. Design and generate an immunostimulatory RNA that can be packaged into HIV 
VLPs.  
 
 
 
 
Figure 6. Overarching hypotheses of this thesis
Here we assess whether packaged RNA within VPs can augment antigenicity and latency 
reversal capacity through interactions with cellular pattern recognition receptors when HIV 
VPs are endocytosed by antigen-presenting cells like DCs. 
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Chapter 2 – Materials and Methods   
2.1 Generation of HIV-derived VLP and VP 
VLPs and VPs were generated as described previously in detail 158. Briefly, serum from 
HIV+ volunteers infected with subtype B virus were collected, and viral RNA was extracted 
using viral RNA isolation kit (Qiagen, USA) according to manufacturer instructions. Viral 
genomic RNA was subsequently reverse transcribed using Superscript III reverse 
transcription kit and random hexamer primers (Thermofisher, CA) adhering to 
manufacturer instructions. This yielded two overlapping 5’ and 3’ cDNA fragments that 
were cloned into an in-house yeast recombination vector, pREC ΔGag/URA3 using a 
yeast-based recombination system described previously 159. Both VP and VLP-encoding 
vectors contained a deleted 5’ LTR and non-functional integrase. However, the VLP-
encoding vector contained extensive mutations in the HIV packaging structure (Ψ), unlike 
the VP-encoding vector, which contained an intact Ψ. 
Following recombination, successful transformants were positively selected on complete 
yeast media plates lacking uracil and containing 5-fluoroorotic acid (5-FOA). 
Untransformed yeast cells contain a URA3 gene that converts 5-FOA into toxic 5’ 
fluorouridine monophosphate, thereby severely impairing cell growth. Recombinant 
plasmid DNA was extracted from yeast using a standard phenol-chloroform isolation 
before transforming into DH5α bacteria and purifying the recombinant plasmid using a 
plasmid DNA maxiprep kit (Qiagen).  
HEK 293T cells were cultured at 37˚C and 5% CO2 in T-175 flasks until cells reached 70% 
confluency. Cells were then transfected with 20 µg of VLP/VP-encoding plasmid per flask 
using 80µL of polyethylenimine (1mg/mL) and cultured for an additional 72 hours. To 
generate adjuvanted VLPs, cells were transfected with 10 µg of VLP-encoding plasmid 
and 10 µg of plasmid encoding the immunostimulatory RNA. Particles were purified 
through 100 kDa MWCO centrifuge tubes (Millipore, CA) before pelleting particles using 
ultracentrifugation at 100,000 G (Beckmann, USA). Virus pellet was resuspended in PBS, 
aliquoted, and subsequently stored at -80˚C until required.    
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2.2 p24 Enzyme-Linked Immunosorbent Assay (ELISA) 
A high binding 96-well plate (Sigma-Aldrich, CA) was coated with pp267 (NCI, 
Frederick), which is a polyclonal anti-p24 antibody. After diluting at 1:1000 in PBS, each 
well was coating with 100 µL of pp267 solution at 37 ˚C for 2 hours, or 4 ˚C overnight. 
The plate was subsequently washed three times in PBS with 0.05% Tween-20 (Sigma, 
CA). Then, 200 µL of blocking solution (PBS + 10% fetal bovine serum) was added to 
each well before incubating for 30 minutes at room temperature. The blocking solution 
was then discarded before washing the plate three times as previously rdescribed. 
Following this, 100 µL of transfection supernatant serial dilutions were loaded in 
duplicates in addition to a p24 standard (NCI, Frederick), the latter of which was run in 
duplicate starting at 10,000 pg/mL down to 156.25 pg/mL. All wells then received 11µL 
of 0.031M Triton X-100 (Thermo Fisher, CA). After incubation at 37 ˚C for 2 hours, 100 
µL of the primary antibody solution (complete DMEM supplemented with 0.1% rabbit 
anti-p24 antibody and 2% normal mouse serum) was added and incubated at 37 ˚C for 1 
hour. Subsequently, 100 µL of the secondary antibody solution (complete DMEM 
supplemented with 0.05% goat anti-rabbit IgG conjugated to HRP, 2% normal mouse 
serum, and 5% normal goat serum) was added to each well and incubated at 37 ˚C for 1 
hour. The reaction was developed by adding 100 µL of TMB (Seracare, Milford, MA) for 
15 minutes before inactivating the reaction by adding 100 µL of 0.5M H2SO4. The plate 
was subsequently read at 450 nm on a Cytation 5 Imaging Reader (BioTek). 
2.3 PBMC Isolation from Whole Blood 
PBMCs were isolated from whole blood using density centrifugation in SepMate™ columns 
according to manufacturer’s protocol. Briefly, 15 mL of Ficoll-Paque™ was pipetted into 
the central hole of the SepMate™ insert. Following this, whole blood from donors were 
diluted in an equal volume of PBS + 2% FBS and carefully added to the column to prevent 
any sample from entering the central hole. Columns were then centrifuged at 1200 G for 
10 minutes at room temperature. Subsequently, the top layer containing the enriched 
population of mononuclear cells was carefully poured into a new tube. PBMCs were then 
washed twice with 20 mL of PBS + 2% FBS before centrifugation at 300 G for 8 minutes 
4 
 
before resuspending the PBMCs in an appropriate volume of 90% FBS and 10% PBS and 
aliquoted into cryotubes for storage such that each vial contained 1 × 10$ cells.  
2.4 Dynamic Light Scattering  
Before loading the appropriate sample onto the DynaPro dynamic light scattering 
apparatus (Wyatt Technology, CA), it was diluted 100-fold in 1X PBS, and 10 µL of 
sample was loaded into a glass cuvette at 25 °C. Twenty independent read events were 
collected for each sample for analysis.  
2.5 Latency Reversal Assays 
PBMCs were isolated from HIV+ donor whole blood as previously described. The 
volunteers used in these studies were diagnosed and cART treated at acute stage of HIV 
infection and were able to suppress viremia to <50 copies HIV-1 RNA/mL. Additional 
inclusion criteria include that the volunteers were on cART for >6 months and had no 
detectable viral blips. On day 0, PBMCs were seeded into T-175 flask (ThermoFisher, CA) 
with RPMI-1640 growth media (Wisent, CA) supplemented with 300 mg/L of L-
Glutamine, 10 U/mL Penicillin, 10 U/mL Streptomycin, and 10% heat-inactivated fetal 
bovine serum (Wisent, CA). To generate monocyte-derived dendritic cells (MDDCs), 
PBMCs were plastic-adhered for 2 h, after which the media was supplemented with 500 
U/mL IL-4 and 1000 U/mL GM-CSF. After culturing cells for 6 days, the MDDCs were 
pulsed with VLPs by co-culturing DCs with VLP (5 µg/mL based on p24). On the same 
day, 1 × 10% autologous T cells were purified from PBMCs using a magnetic-bead 
negative selection kit (Milltenyi Biotech, CA) Briefly, non-CD4+ T cells were labelled 
with biotin-conjugated antibodies, which were then magnetically labelled. CD4+ T cells 
were then isolated through the depletion of magnetically labelled cells. and were used the 
following day. Pulsed MDDCs and autologous T cells were co-cultured for 6 days with 
media being replaced every 3 days. Latency reversal was measured by IFN-γ ELISpot, as 
a proxy for T cell activation, and copies of HIV RNA in culture supernatant corresponding 
to recrudescent virus was measured by qRT-PCR using 5’LTRPA primers binding to the 
5’ HIV LTR.   
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2.6 Yeast-based DNA Recombination 
Saccharomyces cerevisiae was scraped from a YPD starter culture plate and grown 
overnight in YPD media at 37 °C on a shaking incubator at 225 RPM. The following day, 
the culture was centrifuged at 2377 g for 5 minutes. The supernatant was discarded, and 
the yeast pellet was washed with 1 mL of deionized water. This was subsequently 
centrifuged at 1946 G for 5 minutes. The supernatant was subsequently removed, and the 
pellet was resuspended in 500 μL of 0.155 M lithium acetate (pH 7.5) and 0.15M Tris-
EDTA (TE) buffer (pH 8.0) and incubated for 2 hours at 30 °C. Subsequently, the 
recombination mixture was assembled by mixing 100 μL of the yeast mixture with 600 µL 
polyethylene glycol (PEG) mixture (600 µL 10X lithium acetate solution, 600 µL 10X 
Tris-EDTA buffer, and 4.8 mL of 50% w/v PEG BioExtra 3350) (Sigma-Aldrich, CA). 
The recombination mixture was incubated at 30 °C for an hour before incubating for an 
additional 15 minutes at 42 °C. Yeast were then centrifuged at 1946 G for 5 minutes and 
resuspended in 200 μL of water before plating on CSM–Leu+5-fluoro-1,2,3,6-tetrahydro-
2,6-dioxo-4-pyrimidine carboxylic acid (FOA)-containing plates. Yeast clones that 
successfully displaced the orotidine-5'-phosphate decarboxylase (URA3) gene with the 
DNA fragment(s) of interest within the backbone pREC ΔGag–U3 vector grew on this 
media. However, colonies that retain the URA3 gene do not grow as the URA3 gene 
converts FOA in the media into fluorouracil, a toxic metabolite. Leucine dropout media 
was used for additional auxotrophic selection to ensure the yeast colonies that grew 
contained the pREC ΔGag–U3 backbone, which contained the beta-isopropylmalate 
dehydrogenase gene (LEU2) for retention of transformed yeast when grown in the absence 
of leucine. After 72h of growth at 30 ˚C, colonies were isolated and recombinant DNA was 
isolated.  
2.7 Yeast DNA Extraction 
S. cerevisiae colonies that were grown on CSM–Leu+5-FOA plates were collected and 
placed into an Eppendorf tube with 0.3g of 425–600 µm acid-washed glass beads (Sigma-
Aldrich Canada). Into this, 200 µL of breaking buffer was added (2% v/v Triton X-100, 
1% w/v sodium dodecyl sulphate solution, 100 mM NaCl, 10 mM pH 8.0 Tris-Cl, 1 mM 
pH 8.0 EDTA). Once the yeast solution was completely homogenized, 200 µL of 24:25:1 
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(v/v) phenol:chloroform:isoamyl alcohol was added to the mixture before vortexing for 2 
minutes at 300 G. The solution was subsequently centrifuged at 18000 G before 50 µL of 
the top aqueous layer containing DNA was extracted. Afterwards, 10% (w/v) 3M pH 5.2 
sodium acetate solution was added to the solution with 100 µL of cold anhydrous ethanol 
to precipitate the DNA. To pellet the DNA, the mixture was mixed well and incubated at 
–20 ˚C for 20 minutes, before centrifuging at 18000 G for 12 minutes. The DNA pellet was 
washed with 70% ethanol and centrifuged for 30 seconds at 18000 G before resuspending 
in 30 µL of RNAse/DNAse-free H2O.  
2.8 Transmission Electron Microscopy  
As described previously158, HEK 293T cells transfected with VP or VLP were collected in 
15 mL conical tubes and centrifuged at 175 G for 10 minutes to pellet the cells. Cells were 
then washed with cacodylic acid (pH 6.5) before resuspending the cell pellet with 500 µL 
of 2.5% (v/v) glutaraldehyde in sodium cacodylate. Cells were then centrifuged and 
resuspended in 1% (w/v) osmium tetroxide in sodium cacodylate, and subsequently shaken 
for 1h. To dehydrate samples, cell pellet was resuspended in 1 mL of increasing 
concentrations (v/v) of acetone (30%, 50%, 70%, 90%, 95%, and 100%) for 10 minutes 
each. Following these washes, the sample was serially resuspended in increasing amounts 
of TEM Araldite Resin, while amount of acetone was reduced. This was continued until all 
the acetone was completely replaced by the resin. Samples were baked at 60 ˚C for 48h to 
solidify the resin. The samples were subsequently cut into 70nm thick sections using an 
UltraCut UltraMicrotome (Sorvall). Slices were then mounted onto copper meshing and 
stained with uranyl acetate. After allowing the samples to dry, they were stained with lead 
citrate and subsequently washed with sterile water. Samples were subsequently air-dried 
and imaged on a Phillips CM10 TEM machine.   
2.9 In vitro Transcription of PCR Products to Generate RNA 
Constructs   
The RNA was amplified by PCR using primers containing the T7 RNA polymerase 
promotor sequence. Resulting amplicons were used for downstream in vitro transcription 
using a MEGAscript™ transcription kit (ThermoFisher, CA). As per manufacturer 
instructions, a 20 µL reaction was assembled using 2µL of each ribonucleotide (ATP, CTP, 
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GTP, UTP) with 2 µL of 10X reaction buffer, 0.15 µg of PCR product template, and 2 µL 
of the T7 enzyme mix. The reaction was incubated at 37 ˚C for 16 hours, to increase the 
number of transcription initiation events required to synthesize large mass quantities of 
RNA.  
2.10 RNA Secondary Structure Prediction  
RNA sequence was inputted to an online RNA prediction server, which combined four 
structure prediction and analysis algorithms. Specifically, the partition function algorithm 
determined the most probable base-pairing scheme for the RNA molecule. The minimal 
free energy structure was subsequently calculated to determine an overall secondary 
structure that minimizes the Gibbs free energy of a given RNA conformation. In addition, 
the minimal free energy structure was compared to the RNA structure predicted by the 
maximum expected accuracy model to generate the most likely secondary structure. 
Finally, an algorithm detecting RNA pseudoknots was run before displaying the final 
secondary structure.   
2.11 Human PBMC Antigenicity Assays  
2.11.1 Determining antigenicity of VP and VLPs  
PBMC were isolated from healthy donors (n = 5) using density gradient centrifugation 
(Milltenyi Biotec, CA). Cells were resuspended in RPMI before plating into 96-well plates 
with 106 293T cells/well.  Each well received 5 µg/mL (based on p24) of either VP or VLP. 
Positive control wells were treated with either 10 µg/mL ORN02/LyoVec™, an AU-rich 
oligonucleotide complexed with a lipid-based transfection reagent, or with 2 µL/mL of 
PMA/Ionomycin cell stimulation cocktail (ThermoFisher Scientific, CA). Cells were then 
incubated at 37 °C and 5% CO2 for 24h before collecting cell culture supernatant for 
detection of TNFα by ELISA using manufacturer’s guidelines (Mabtech, USA). Briefly, 
0.5 mg/ml mixture of anti-TNF3/4 mAb capture antibody (Mabtech, USA) was adsorbed 
to each well of a high-binding 96-well microplate before blocking with 1X PBS + 0.05% 
Tween® + 1% BSA overnight at 4 °C. On the following day, 100 µL of culture supernatant 
from pulsed PBMC were loaded onto wells before incubating at room temperature for 2 
hours and washing with 1X PBS + 0.05% Tween®. Subsequently, 1 µg/mL of biotinylated 
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monoclonal antibody TNF5 was added before incubating for 1 hour and adding 
Streptavidin-HRP diluted to 1:1000 and incubating for an additional hour.  
The plate was washed before developing the ELISA reaction with 100 µL of 
tetramethylbenzidine substrate solution (Seracare, Milford, MA). The reaction was stopped 
with 1N H2SO4 and absorbance was read at 650nm using a spectrophotometer (BioTek, 
USA).  
2.11.2 Determining Antigenicity of RNA Constructs    
PBMC from healthy donors (n = 5) were resuspended using density gradient centrifugation. 
Cells were subsequently plated at 5 × 10'cells/well in a 96-well plate. After resting 
PBMCs overnight, cells were transiently transfected with 5 µg of RNA using 10 µg/mL of 
dioleoyl-3-trimethylammonium propane (DOTAP). Specifically, RNA was incubated with 
DOTAP in incomplete RPMI for 15 minutes before adding into respective wells.   
2.12 Latency Reversal Assays  
Latency reversal assays were carried out as previously described (manuscript under 
review). Briefly, PBMC were isolated from acutely infected HIV+ donor before enriching 
resting CD4+ T lymphocytes using negative depletion CD4+ T cell isolation kit (Miltenyi 
Biotec, USA). Autologous monocyte-derived dendritic cells (MDDCs) were generated by 
plastic adherence of monocytes from the negative depletion filtrate. These cells were 
cultured for six days in media supplemented with GM-CSF (1000 U/mL) + IL-4 (500 
U/mL), as previously described 160. On the sixth day, MDDCs were pulsed with either VP 
or VLP. For TLR stimulation experiments, MDDCs were treated with TLR agonists: 
Imiquimod (1 µg/mL) or ssRNA40/LyoVec™ (5 µg/mL). Additional treatments involving 
combinations of TLR agonist and VLP were also tested. The following day, CD4+ T cells 
were co-cultured with pre-treated, autologous, pulsed MDDCs. To prevent de novo 
infection of uninfected cells by reactivated latent virus, 10 µM of Enfuvirtide, a fusion 
inhibitor, was added to the culture before incubating for 24 hours at 37 °C and 5% CO2. 
Degree of latency reversal was determined as a function of amount of induced virus in 
culture supernatant (measured by qRT-PCR detecting HIV RNA in cell-free supernatant), 
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and T cell activation (measured by human IFN-γ, detected by enzyme-linked 
immunosorbent assay (ELISpot) assay.  
IFN-γ ELISpot was used to quantify T cell activation. Plates containing pre-coated layer 
anti-IFN-γ antibodies were washed with PBS before blocking for 30 minutes with complete 
RPMI. Following a wash step, the MDDC-pulsed CD4 T cells were plated at 1 × 10%  
cells/mL and incubated for 16h at 37 °C and 5% CO2. Wells containing unstimulated T 
cells in complete RPMI media served as negative controls. Biotinylated anti-IFN-γ 
antibody was added at 1 μg/ml for 2h and subsequently washed and incubated with 
streptavidin-HRP for 1h. To detect spots, 100 µL of TMB substrate was added to each well 
after thoroughly washing plates with PBS.  
2.13 Quantifying Packaged RNA within HIV Particles  
To quantify the amount of packaged RNA within particles, viral RNA from culture 
supernatant was isolated using a QIAamp Viral RNA Mini Kit (Qiagen, USA). First-strand 
cDNA synthesis was subsequently performed using SuperScript III First-Strand Synthesis 
System for RT-PCR (Invitrogen, CA), according to manufacturer instructions. The cDNA 
was stored at -20°C or used immediately for 2-step qRT-PCR. Irrespective of which primer 
set was employed, reactions were assembled with 10 µL of 2X PowerUp™ SYBR™ Green 
Master Mix, 500 nM primers, and 1 μL of cDNA template. Final reaction volume of 20 μL 
was achieved with the addition of water before being run on a QuantStudio 5 RT-PCR 
system. To detect viral genomic RNA, a Gag-specific primer set (GagF + GagR) was 
employed, whereas recrudescent virus in latency reversal assays were detected using 
5’LTRPA, a primer landing on the 5’ LTR. To detect RNA adjuvants, unique barcode-
specific primer sets–located within the RNA adjuvant constructs–were employed. The 
qRT-PCR reaction was carried out by holding temperature at 50°C for 2 minutes for uracil-
N-glycosylase activation, followed by a 95°C incubation for 2 minutes for DNA 
polymerase activation. Forty cycles of PCR were subsequently carried out, where each 
cycle consisted of a denaturing phase at 95°C for 15 seconds, an annealing phase at 60˚C 
for 15 seconds, and an extension phase at 72˚C for 1 minute. Copies of RNA were then 
normalized to p24 levels. 
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2.14 Statistical Analyses  
Statistical analyses were performed using GraphPad Prism version 8.0 (GraphPad 
Software, San Diego, CA). A statistically significant difference was defined when the P 
value was <0.05 by paired Student’s t test, unpaired Student’s t test, or Friedman test 
with Dunn’s multiple comparisons tests.  
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Chapter 3 - Results  
 
3.1 Co-formulating HIV VLP with Exogenous TLR7 Adjuvant, 
ssRNA, Augments HIV-1 Latency Reversal 
In a subset of memory CD4+ T cells within infected donors, HIV persists as a stably 
integrated provirus. Although most proviruses are defective, a subset of memory CD4+ T 
cells harbor fully-intact replication competent provirus, and constitute the majority of the 
latent reservoir161. To date, it has been impossible to distinguish cells harboring latent HIV 
from uninfected cells. Our research team has previously hypothesized that the latent 
reservoir might preferentially reside within resting memory CD4+ T cells bearing TCRs 
specific for HIV antigens. This may be especially true during acute HIV infection where 
responding CD4+ T cells are at increased risk of infection due to their activated state. If 
this hypothesis is true, reactivation of these cells through the TCR using HIV antigens may 
allow for transcriptional reactivation of the proviral reservoir162. Previous data from our 
lab suggests that our VLPs immunotherapy, which displays HIV antigens from the 
reconstructed quasi-species of five HIV infected individuals, induces greater latency 
reversal than clinically relevant latency reversal agents (manuscript under review). At the 
same time, several published studies have described the latency reversal potential of certain 
TLR agonists in cell lines and primary cells138,163,164. In particular, the capacity of TLR7/8 
agonists to induce latency reversal in vitro has been well described165–169.   
As our research team has data to support VLP-mediated latency reversal, we hypothesized 
that adding in an exogenous adjuvant to the VLP formulation might enhance the latency 
reversal and overall T cell activation that we detect in our latency reversal assays. 
Therefore, we chose to adjuvant our VLP formulations with TLR agonists to determine 
whether the observed VLP-mediated latency reversal could be increased. Various 
combinations of TLR ligands were added to VLP formulations, including 
polyinosinic:polycytidylic acid (polyI:C), Imiquimod, and ssRNA which activate TLR3, 
TLR7, and TLR8 respectively. CD4+ T cells were purified from whole PBMC isolated 
from HIV– or HIV+ donors. Autologous MDDCs were then pulsed with VLP in the 
presence or absence of TLR agonists (Fig 7A). MDDCs were then co-cultured with CD4+ 
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T cells at a ratio of 1:4. Copies of genomic RNA from induced virus was quantified by 
qRT-PCR, which utilized an optimized primer set and qRT-PCR assay that binds to the 5’ 
LTR158. The ability of the qRT-PCR assay to discriminate RNA from induced virus as 
opposed to nucleic acids associated with the VLPs used to pulse MDDC is based on three 
properties: 1) our latency reversing VLPs that are pulsed into MDDCs are genomeless and 
therefore do not contain packaged RNA, 2) the VLPs have a mutagenized integrase enzyme 
and therefore cannot perform integration, and abrogates RNA genome packaging170 and 3) 
the plasmid DNA of the VLP constructs lack a 5’ LTR preventing any potential for reverse 
transcription, which precludes RNA genome packaging. T cell activation was measured by 
commercially available IFN-𝛾	ELISpot.  
CD4+ T cells from HIV+ donors that were co-cultured with MDDCs pulsed with either 
VLP alone or with Imiquimod induced detectable levels of HIV-1 RNA in culture 
supernatants, however was not significantly different from unstimulated media control. In 
contrast, MDDCs treated with Poly(I:C) or ssRNA induced significantly higher HIV RNA 
than unstimulated media control. MDDCs pre-treated with Poly(I:C), Imiquimod, or 
ssRNA before pulsing with VLP were all able to induce significantly higher HIV RNA 
from CD4 T cells than unstimulated media control (Fig 7B). With respect to T cell 
activation, there was no statistically significant difference between IFN-γ secretion from T 
cells after co-culturing with MDDCs pulsed with either VLP alone or pre-treated with 
Poly(I:C) or Imiquimod. However, when T cells were co-cultured with MDDCs that were 
pre-treated with ssRNA, it induced significantly more IFN-γ than unstimulated media 
control. Likewise, T cells released significantly higher IFN-γ in response to co-culturing 
with MDDCs pulsed with a combination of ssRNA + VLP, Imiquimod + VLP, and 
Poly(I:C) + VLP (Fig 7C).  
To demonstrate that the HIV RNA that was measured in our latency reversal assays was 
specific for induced virus and not from our VLPs, we quantified viral RNA in culture 
supernatants from MDDC-CD4 T cell co-cultures derived from HIV negative donor 
PBMC.  This also enabled us to evaluate the antigenicity of the VLPs and TLR agonists in 
healthy donor samples, thereby verifying that the stimuli used were immunostimulatory. 
As expected, no HIV RNA was detected in the negative control culture conditions where 
MDDCs from healthy donors were pulsed with VLP alone or pre-treated with TLR 
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agonists, before co-culturing with autologous T cells. Likewise, MDDCs treated with 
various combinations of VLP and TLR agonists did not induce detectable HIV RNA in 
culture supernatant after co-culturing with autologous T cells (Fig 7D). This suggested that 
the assay was detecting induced virus and that the VLPs were not being detected in this 
system. MDDCs from HIV– donors treated with Poly(I:C) induced significantly higher 
IFN-γ secretion from co-cultured T cells, whereas MDDCs treated with Imiquimod or 
ssRNA did not induce a statistically significant difference in IFN-γ secretion from co-
cultured T cells. Interestingly, MDDCs pulsed with combinations of VLP and TLR 
agonists were able to induce IFN-γ secretion from T cells; however, these phenomena were 
not statistically significant (Fig 7E). Taken together, these results suggest that VLP-
mediated latency reversal may be enhanced by the inclusion of TLR agonists such as 
ssRNA. 
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Figure 7. Adjuvanting VLPs with exogenous ssRNA augments latency reversal 
Human PBMC from HIV+ donors (n = 4) or HIV– donors (n = 5) were used to isolate CD4 
T cells, which were subsequently stimulated with autologous monocyte-derived dendritic 
cells (MDDCs) pulsed with combinations of VLP and TLR agonists. T cell activation 
measured by ELISpot IFN-γ spot forming units (SFU) per 106 CD4 T cells. Copies of 
recrudescent virus measured by qRT-PCR, which employed a primer set that targets the 
HIV 5’ LTR.  (A) Experimental timeline and flow. (B) Copies of recrudescent virus 
released from T cells isolated from HIV+ PBMC. (C) IFN-γ secretion from T cells isolated 
from HIV+ PBMC. (D) Copies of recrudescent virus released from T cells isolated from 
HIV– PBMC. (E) IFN-γ secretion from T cells isolated from HIV– PBMC. Results are 
presented as mean ± SEM of HIV copy number or IFN-γ SFUs. Student’s t tests were 
performed to compare results to unstimulated media control.  *p<0.05.   
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3.2  VPs containing packaged viral genomic RNA were 
more antigenic than packaging-deficient VLPs  
During the construction of our latency reversing VLP formulations, we purposefully 
constructed formulations that would not contain HIV genomes. This was done for safety 
reasons and with one eye on future testing in non-human primates and eventually in human 
clinical trials. Since our previous data suggested that TLR agonists, like ssRNA could 
augment VLP antigenicity, we hypothesized that by eliminating the ability of the HIV 
genome from packaging in our VLPs, we might have inadvertently reduced the latency 
reversal potential of our VLP formulations.  Therefore, we sought to identify the antigenic 
contribution of packaged HIV RNA within viral particles (VP) and compare it to our VLP 
formulations. To do this, we generated a novel particle construct, encoding a VP-generating 
vector with the ability to package its own defective genome i.e. with a functional y and 
without the ability to reverse transcribe (D 5’LTR) or have functional integrase. This VP 
formulation was then evaluated against the previously made VLP-encoding vector which 
contained a severely mutated Ψ (preventing RNA packaging) and without the ability to 
reverse transcribe (D 5’LTR) or have functional integrase. It is therefore important to note 
that apart from the abilities to package or not package their respective RNAs, the VPs and 
VLPs are structurally and proteomically identical (Fig 8A).  
To characterize the particles that were produced from both constructs, TEM was first 
performed to visually assess the structure and size of the generated particles. The VPs and 
VLPs that were produced from HEK 293T were morphologically identical to each, 
displaying an immature virion phenotype and a size of ~120 nm (Fig 8B). To assess the 
quantity of packaged RNA within VPs and VLPs, viral RNA was extracted from lysed 
particles and cDNA was synthesized using random hexamers. Following this, qRT-PCR 
was used to quantify the amount of packaged RNA using a primer set specific for HIV 
Gag. Copies of RNA were subsequently normalized to p24. Quantity of packaged RNA in 
VLP was then expressed as a percentage of packaging compared to VPs. Although both 
VP and VLP constructs produced morphologically similar particles, VLPs contained 21% 
of packaged RNA compared to VPs, which was a statistically significant difference 
(p<0.0001). No HIV RNA could be detected in media devoid of VP or VLP (Fig 8C). 
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As mentioned previously, single stranded RNA is a known TLR7 agonist. Therefore, its 
presence in VPs should increase their abilities to trigger innate antiviral immune responses. 
To assess if there were any antigenic differences between the VPs and VLPs due to the 
presence or absence of packaged RNA, PBMCs from healthy donors (n = 5) were co-
cultured with VPs or VLPs for 24h, 48h, or 72h. A global T cell activator, phorbol 12-
Myristate 13-Acetate/Ionomycin (PMA/Iono), was used as an assay positive control. A 
TLR7/8 agonist, ORN02/LyoVec™, which is an AU-rich oligonucleotide complexed with 
a lipid-based transfection reagent, was also employed as an additional assay control. As 
shown, the VPs induced significantly greater TNFα (455 pg/ml) production in PBMCs than 
VLPs (84 pg/ml) after culturing for 24h and then again after 48h (p<0.05); however, the 
levels of TNFα- in some samples were below the sensitivity of the assay by 72h (p≥0.05), 
indicating there is a short 48h window in which to detect TNF-α production from human 
PBMC (Fig 8D). These results collectively suggest that virally packaged RNA in VPs is 
more immunostimulatory than VLPs without encapsidated RNA.  
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Figure 8. VPs containing packaged viral genomic RNA are more immunostimulatory 
than packaging-deficient VLPs. 
VPs and VLPs were generated by transfecting VP-encoding constructs or VLP-encoding 
constructs into HEK 293T cells for 72 hours (A). After purifying virus through 
ultracentrifugation, structural integrity of particles was interrogated using TEM (B), and 
packaged genomic material was quantified by qRT-PCR (C). Scale bars are 100 nm. 
PBMCs from healthy donor (n = 5) were subsequently stimulated with 5 µg/mL VP, 5 
µg/mL VLP, 5µg ORN02, or 1X PMA/Ionomycin. Cell activation was measured as a 
function of TNF-α in culture supernatant 24h, 48h, and 72h post-stimulation (D). Data 
are represented as mean ± SEM. An unpaired Student’s t test was used to compare 
packaging between VP and VLPs, whereas a paired Student’s t test was used to compare 
TNF-α induction in PBMCs stimulated with either VP or VLP. ****p<0.0001, *p<0.05. 
Ψ; HIV packaging signal.  
 
3.3 VPs induce greater latency reversal than VLPs in HIV+ 
PBMCs 
Since VPs were more immunostimulatory than VLPs in cultures of healthy human PBMCs, 
we sought to characterize, if any, the effect of packaged viral RNA on latency reversal. To 
do this, PBMCs were isolated from HIV+ donors (n = 6) and latency reversal assays were 
carried out as described in Fig 9A. Briefly, VPs or VLPs were used to pulse MDDCs from 
HIV+ PBMC and then co-cultured with autologous CD4 T cells. Latency reversal was 
measured as a function of T cell activation and induced HIV copy number in culture 
supernatants. As shown (Fig 9B), significantly more IFN-γ was released from T cells that 
were co-cultured with MDDCs pulsed with VPs compared to VLPs in all 6 donors 
(p<0.05). Although elevated concentrations of HIV RNA were detected in culture 
supernatants from cells derived from 4/6 donors, this was not statistically significant (Fig 
9C). Despite the lack of statistical significance, there may be some biological significance 
for HIV cure due to the low frequency of latently infected cells. Additionally, the VLPs 
are a heterologous formulation to the virus that infected the CD4 T cells, meaning the 
MDDC presented peptides might not be a perfect match for T cell activation in all cases. 
As a result, small changes in the data, albeit not statistically significant, could have some 
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biological significance. Alternatively, it is possible in the two donors in which no increase 
in HIV RNA was detected, that the VLPs had reactivated the entirety of the reservoir from 
the cells. Collectively, the results suggest that virally packaged HIV RNA is capable of 
augmenting both particle antigenicity and potential of latency reversal.  
Figure 9. VPs induce greater latency reversal than VLPs in HIV+ PBMCs.  
CD4 T cells from HIV+ PBMC (n = 6) were stimulated with autologous MDDCs pulsed 
with either VP or VLP (A). CD4 T cell activation was measured by ELISpot as a function 
of IFN-γ SFUs per 106 CD4 T cells (B), whereas copies of recrudescent virus were 
measured by qRT-PCR employing a primer set that bound to the 5’ LTR (C). Data are 
displayed as mean values and each line represents matched responses from each donor. 
*p<0.05 using paired Student’s t test. 
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3.4 Design of packaging-competent immunostimulatory 
RNA adjuvants to replace HIV genomic RNA in VPs  
Although the packaging of RNA into VPs can significantly increase the T cell stimulatory 
capacity of the formulation when presented by MDDC, the increase in amount of HIV 
RNA that was detected in culture supernatants was not statistically significant compared 
to the VLP formulation. This is despite increasing the detectable HIV RNA in culture 
supernatants in most samples tested (4/6 donors). These results suggest that the inclusion 
of an RNA component into the VLP formulation can enhance its latency reversal properties 
and therefore enhance the overall efficacy as an LRA. This is especially true given all 
inducible proviruses must be extracted from the cellular reservoir in order to achieve a 
sterilizing cure. Hence even a non-significant increase in the detected HIV RNA upon 
latency reversal is likely to have biological significance. Therefore, we hypothesized that 
incorporating a safe adjuvanting RNA, with the potential to trigger and augment proviral 
transcriptional reactivation from the cellular reservoir, may increase the efficacy of VLPs 
as a potential immunotherapeutic strategy for HIV cure. With this in mind, we constructed 
adjuvanting RNAs with the capacity to be packaged within VLPs.  To do this we 
synthesized RNAs based on “GC” and “AU” rich content as they had previously been 
shown to preferentially induce IFN-α and TNF-α biased cytokine profiles based on their 
sequence specificity for TLR7 and TLR8171.  
Using these GU and AU rich motifs, we designed a packaging-competent 
immunostimulatory DNA vector, which could be transcribed in vivo by utilizing a CMV 
promotor. In addition, the inclusion of an upstream T7 RNA polymerase promotor enabled 
in vitro transcription. A cis-acting packaging signal was then designed upstream of the 
immunostimulatory region and downstream of the CMV promotor, allowing ssRNA to be 
packaged into VLPs upon co-transfection with the VLP-encoding vector to produce 
adjuvanted VLPs. Three RNA adjuvants were generated, and each differed in GU or AU 
content. These include a Multi RNA adjuvant containing repeat motifs of two “GC”-rich 
domains: (GUUC)25 + (GUCC)25, and two “AU”-rich domains: (AUGU)25 + (UAUU)25. 
Single adjuvants expressing either, (GUUC)25, or (AUGU)25 were also made (Fig 10A–C). 
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To determine the structure of these RNA adjuvants, positional entropy was calculated for 
each nucleotide and used as a basis to calculate the most energetically favorable structure 
using an in silico RNA folding algorithm172. All RNA adjuvants were determined to have 
favorable folding entropies with ∆G < 0. The Multi adjuvant had the most favorable folding 
entropy at -250.30 kcal/mol, followed by the GUUC adjuvant (-193.60 kcal/mol). The 
AUGU adjuvant, had the least favorable folding entropy of the three at -182.00 kcal/mol. 
Interestingly, there were some regions in the adjuvants where positional entropy 
approached +4.4 J/K in the Multi (Fig 10A) and GUUC (Fig 10B) RNA adjuvants, whereas 
the AUGU RNA adjuvant had a stretch of 3 nucleotides whose positional entropy 
approached +2.2 J/K (Fig 10C). Since the positional entropies are greater than 0 kcal/mol, 
it signifies that these stretches of nucleotides are in unfavorable conformations. However, 
the packaging signal for all adjuvants were clearly marked by two stem loop structures, 
characteristic of SL1 and SL2, which are the stem-loop structures found in Ψ that confer 
RNA packaging. 
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Figure 10. Design of Packaging-competent RNA Adjuvants.  
Above each of the predicted structures is the schematic of the DNA vector used to 
generate the RNA adjuvants. The length of each immunostimulatory domain is given by 
the subscripted number in the schematic above each RNA fold structure. The blue 
highlight region downstream of the CMV promotor and upstream of Ψ in each of the 
adjuvant corresponds to a 5’ LTR deletion. The predicted structure is color-coded based 
on the positional entropy of each nucleotide. The HIV packaging signal is highlighted in 
green. Predicted structure of (A) Multi (B) GUUC and (C) AUGU adjuvants are shown.  
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3.5 Addition of DOTAP to RNA adjuvants generates particles  
After generating DNA vectors that encoded the immunostimulatory RNAs, we sought to 
characterize its innate antigenicity. To do this, linear RNA adjuvant fragments were 
generated through in vitro transcription of the RNA adjuvant DNA vector. Briefly, a 5’ 
primer that contained a T7 RNA polymerase promotor site was used in conjunction with 
a 3’ primer that bound to the HIV 3’ LTR. The resulting linear fragments of DNA were 
subsequently used for in vitro transcription using T7 RNA polymerase to generate linear 
RNA adjuvant fragments. These oligoribonucleotides were subsequently complexed 
within cationic lipoplexes capable of delivering the RNA into cells. This was done by 
incubating RNA adjuvants with the cationic lipid dioleoyl-3-trimethylammonium 
propane (DOTAP). To ensure that RNA-lipid complex formation had taken place, and to 
characterize the particles, we measured the size distribution profile for each complex 
using dynamic light scattering (DLS). As shown in Fig 11, the sizes of GUUC, AUGU, 
and Multi RNA in complex with DOTAP were significantly smaller than DOTAP alone 
(p<0.0001), indicating a successful condensation reaction. The sizes of RNA in the 
absence of DOTAP was also measured and was determined to be significantly smaller 
(p<0.0001) than complexes generated with DOTAP. This result suggests that the RNA 
adjuvants can form nanomolecular complexes with DOTAP. There was no discernable 
difference between the differing RNAs to successfully form lipoplexes. Interestingly all 
generated lipoplexes had a size range of 159 – 170 nm, which is only slightly larger than 
the size ranges of HIV-1 virions. 
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Figure 11. Sizes of DOTAP cationic liposome particles with RNA adjuvants.  
RNA adjuvants were first generated by in vitro transcription using T7 polymerase. 
Liposomal particles were generated by incubating 10 µg/mL of DOTAP with 5 µg of 
RNA. Particles were then diluted 100-fold, before loading 10 µL of the prepared sample 
into a dynamic light scattering device capable of characterizing particle size distribution. 
Data are representative of twenty independent read events and are expressed as means ± 
SEM. ****p<0.0001 by unpaired Student’s t test.  
 
3.6 RNA adjuvants are immunostimulatory and trigger IRF 
and NF-κB responses in a THP-1 Dual reporter cell line  
Before making adjuvanted particles with encapsidated RNA, we evaluated the ability of 
the various RNA adjuvants to induce immune activation by measuring their ability to 
activate key transcription factors. Both interferon regulatory factor (IRF) and NF-κB are 
key signaling molecules which are heavily involved in enacting innate antiviral immune 
responses and inflammation173. To test the RNA adjuvants, the various adjuvanting 
RNAs were complexed with DOTAP to form lipoplexes as previously described. The 
lipoplexes were then used to stimulate THP-1 Dual™ cells, which express Luciferase and 
SEAP under the control of NF-kB and IRF.  In this reporter cell line, the Lucia luciferase 
reporter gene is under the control of the ISG54 minimal promotor with five additional 
IFN-stimulated response elements while the secreted alkaline phosphatase reporter gene 
is driven by five copies of the NF-κB consensus transcriptional response elements with 
three c-Rel binding sites. The IRF pathway activation was determined as a function of 
Lucia luciferase activity (relative light units, RLU) in culture supernatant, whereas NF-
κB pathway activation was determined as a function of alkaline phosphatase levels. As 
assay positive controls, PMA/Iono, GS-9620, and imiquimod were used to stimulate the 
reporter cells.  
All lipoplex formulations using the various RNA adjuvants induced significantly higher 
IRF activation compared to uncomplexed RNA (p<0.0001) or the unstimulated media 
control (p<0.0001) (Fig 12A, B). Specifically, the multi RNA adjuvant, although 191-fold 
more immunostimulatory than the media control, induced the least IRF activation 
compared to the AU-rich and GU-rich RNA adjuvants. In contrast, the AU RNA adjuvant 
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induced the greatest IRF activation (609407 ± 63038 RLU). Lastly, the GU RNA adjuvant 
induced 434545 ± 62001 RLU. Comparatively, minimal activation of the IRF pathway 
was detected when PMA/Iono, GS-9620, and Imiquimod were used as positive control 
stimulations.  
All RNA adjuvants induced significantly higher NF-κB activation when complexed to 
DOTAP, whereas the RNAs alone did not activate NF-κB (Fig 12C). The multi RNA 
adjuvant complexes induced the least NF-κB activation (OD 0.45 ± 0.02321). The 
antigenicity of the multi RNA complexed to DOTAP is significantly greater than the multi 
RNA alone (p<0.01). The AU RNA adjuvant complexes induced the greatest NF-κB 
activation, at OD 0.9 (± 0.1186). When complexed to DOTAP, the AU RNA adjuvant was 
also significantly more antigenic than the AU RNA alone (p<0.0001). The GU RNA 
adjuvant complexes induced OD 0.54 (± 0.07449). The GU adjuvant in complex to 
DOTAP was significantly more antigenic than GU RNA alone (p<0.01). These trends 
persisted when these data were represented as fold increases over media control (Fig 12D). 
The positive controls did induce greater, but non-significant elevations in the levels of NF-
κB when compared to the media control with only with PMA/Iono inducing significantly 
greater NF-κB activation compared to media alone (p<0.0001); however, for GS-9620 and 
Imiquimod, this phenomenon was not statistically significant. Taken together, the results 
suggest that the RNA adjuvants are immunostimulatory and result in NF-kB activation. 
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Figure 12. RNA adjuvants are antigenic and trigger IRF and NF-κB responses in a 
THP-1 Dual Reporter cell line. 
THP-1 Dual™ cells (105 cells/well) were stimulated in a 96-well plate format with 5µg 
RNA adjuvant or with positive controls: 1x PMA/Iono, 2µM GS-9620, or 2 µg/mL 
Imiquimod. Results are from three independent experiments. Cells were cultured for 24h 
at 37 °C and 5% CO2 before assessing IRF and NF-κB activation. Specifically, IRF 
activation was assessed as a function of Lucia luciferase in culture supernatant (A). Data 
were represented as fold increase over media (B). In parallel, NF-κB activation was 
assessed as a function of secreted embryonic alkaline phosphatase levels in culture 
supernatant, which was measured by absorbance readings at 630 nm (C). Data were 
represented as fold increase over media (D). Data are shown as means ± SEM. Unpaired 
Student’s t tests were used to compare groups to media control. **** p<0.0001. **p<0.001. 
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3.7 RNA Adjuvants Trigger Differential TNF-α and IFN-α 
responses in human PBMCs  
As we had previously evaluated the various RNA constructs in the THP-1 model cell lines, 
we subsequently sought to confirm the antigenicity of the various RNA adjuvants in a more 
biologically relevant cell type. Therefore, PBMCs from HIV– donors (n = 5) were 
stimulated with RNA adjuvants complexed to DOTAP and assessed for their secretion of 
IFN-α and TNF-α. In addition, PBMCs were stimulated with PMA/Iono, GS-9620, and 
Imiquimod, all serving as positive assay controls. Donors had varying IFN-α responses to 
the RNA adjuvants and positive controls (Fig 13A). When these IFN-α responses were 
represented as a mean value across the five donors, several trends became apparent. 
Specifically, the GU RNA adjuvant induced significantly greater IFN-α induction 
compared to media control (p<0.0001). In fact, the GU RNA adjuvant induced the greatest 
IFN-α production compared to any of the other RNA adjuvants. The AU RNA adjuvant 
also induced significantly greater IFN-α induction compared to media control (p<0.01). 
The multi RNA adjuvant induced the least IFN-α production and was significantly different 
from media control (p<0.05) (Fig 13B). For comparison, the multi RNA adjuvant and the 
AU RNA adjuvant induced 42% and 55%, respectively, of the IFN-α response elicited by 
the GU RNA adjuvant.  
Donors had varying TNF-α responses towards the RNA adjuvants and positive controls 
(Fig 13C). When responses were expressed as means of the five donors, it became apparent 
that the AU RNA induced the most TNF-α secretion from PBMCs and was significantly 
greater than the media control (p<0.0001). However, the TNF-α induction using the other 
RNA adjuvants were not statistically different compared to the media control. Specifically, 
the TNF-α responses elicited by the multi RNA and GU RNA was only 22% and 28%, 
respectively, of the response elicited by the AU RNA (Fig 13D).   
To determine if the RNA adjuvants had preferential biases towards stimulating an IFN-α 
or a TNF-α response, the ratio of TNF-α secretion to IFN-α secretion for each RNA 
adjuvant was determined (Fig 13E). It was apparent that the responses between the AU 
RNA and the GU RNA adjuvants were statistically different (p<0.005). Specifically, the 
AU RNA adjuvant induced the highest ratio of TNF-α to IFN-α, whereas the GU RNA 
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adjuvant induced the lowest ratio of TNF-α to IFN-α. There was no statistically significant 
difference between the ratio of TNF-α to IFN-α induced by the multi RNA compared to 
either the GU or the AU RNA adjuvants. These results suggest that the sequence identity 
of the RNA adjuvants was capable of skewing immune responses, resulting in a bias 
towards either a TNF-α predominant response, or an IFN-α predominant response.   
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Figure 13. RNA Adjuvants Trigger Differential TNF-α and IFN-α responses from 
human PBMCs 
PBMCs from healthy donors (n = 5) were plated in a 96-well plate format at 5 × 10' 
cells/well. Cells were then stimulated with RNA adjuvants (5 µg) complexed to DOTAP, 
or with positive controls GS-9620 (2 µM), PMA (40.5 µM) + Ionomycin (670 µM), 
Imiquimod (2 µg/mL). After 24h, supernatant was collected to determine IFN-α and TNF-
α levels using an ELISA. Bar graph showing individual donor IFN-α responses to the 
treatment conditions (A). Bar graph showing mean IFN-α responses towards each 
condition (B).  Bar graph showing donor TNF-α responses to treatment conditions (C). Bar 
graph showing mean TNF-α responses towards treatment conditions (D). Bar graph 
showing ratio of TNF-α secretion to IFN-α for each RNA adjuvant (E). Results are 
represented as mean of 3 independent experiments ± SEM. ****p<0.0001, **p<0.005, 
*p<0.05 by Friedman test followed by Dunn’s multiple comparisons tests. 
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3.8 Co-administration of RNA adjuvants increases VLP 
antigenicity in THP-1 cells 
In the most probable future scenario, the RNA adjuvants would be packaged into VLPs for 
safe delivery and to increase its specificity.  However, we sought to initially determine 
whether co-delivery of RNA adjuvants and VLPs was more antigenic than HIV RNA found 
in VPs. This was done to evaluate the potential of the RNA adjuvants as potential co-
delivered adjuvants, should downstream processes that involve packaging RNA adjuvants 
into VLP became problematic. To do this the THP-1 reporter cell line was cultured with 
either VP, VLP, or VLP in the presence of each RNA adjuvant. In addition, cells were 
cultured with Imiquimod or GS-9620 as positive controls. After culturing for 24 hours, IRF 
and NF-κB activation was characterized as described previously. As shown in Fig 14A, 
VLPs that were co-administered with RNA adjuvants induced significantly more IRF 
activation (p<0.0001) than VPs containing HIV RNA. This phenomenon was consistent 
for each RNA adjuvant (GU, AU, and Multi). On average, the IRF response to VLP + RNA 
adjuvant was 97-fold greater than VPs. Likewise, Fig 14B shows that VLPs co-
administered with RNA adjuvants were significantly more capable of activating NF-κB 
than VPs containing HIV RNA (p<0.05). On average, the NF-κB response to VLP + RNA 
adjuvant was 9-fold greater than VPs. Interestingly, in both cases, VPs were significantly 
more antigenic than VLPs (p=0.0249 for NF-κB, and p=0.0068 for IRF), which aligned 
with our previous results.  
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Figure 14. Co-administration of RNA adjuvants increases VLP antigenicity 
THP-1 Dual™ cells were plated at 5 × 10'	cells/well and stimulated with 5 µg of VP or 5 
µg VLP, or 5 µg of RNA adjuvants complexed to DOTAP as previously described. After 
24 h, cells were assessed for IRF and NF-κB activation by interrogating cell culture 
supernatants for Lucia luciferase (A) and SEAP (B), respectively. Results were obtained 
from two independent experiments. Values are represented as means ± SEM. 
****p<0.0001, **p<0.005, *p<0.05 using unpaired Student’s t tests. 
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3.9 Pharmacodynamic inhibition of RNA adjuvant-mediated 
IRF and NF-κB activation  
To characterize a potential mechanism through which the RNA adjuvants elicit IRF and 
NF-κB activation, we sought to determine the effect of various TLR inhibitors on THP-1 
Dual cell activation in response to RNA adjuvants and well-described TLR7 agonists , GS-
9620 and Imiquimod.. To do this, we used synthetic oligodeoxynucleotides (ODN) that 
have been shown to specifically block TLR recognition of nucleic acids by competitively 
inhibiting signaling through TLR7 (IRS-661), or both TLR7 and TLR8 (IRS-954). In 
addition, we used chloroquine, which is a well-described molecule derived from quinoline. 
As a lysosomotropic agent, chloroquine preferentially accumulates within endosomes and 
inhibits TLR signaling through several concerted efforts. Since TLR signaling requires 
endosomal acidification, chloroquine-mediated inhibition of endosomal acidification 
effectively mitigates TLR activation. In addition, chloroquine binds to endosomal nucleic 
acids and occludes TLR-binding epitopes.  
In these inhibitor studies we observed that IRF activation in response to the positive 
controls were significantly lower in the presence of IRS-661, IRS-954, or chloroquine, 
compared to cells that were not treated with inhibitors (Fig 15A). Likewise, NF-κB 
activation induced by the positive controls were significantly lower for cells that were pre-
treated with IRS-661, IRS-954, or chloroquine, compared to cells that were not pre-treated 
with inhibitors (Fig 15B). IRF responses to the RNA adjuvants complexed to DOTAP were 
significantly lower when cells were pre-treated with IRS-661, IRS-954, or chloroquine, 
compared to untreated cells (Fig 15C). Interestingly, IRS-661 and IRS-964 pre-treatment 
was unable to inhibit NF-κB activation for all three RNA adjuvants. However, pre-
treatment with chloroquine seemed to inhibit NF-κB secretion. Even so, this phenomenon 
was only statistically significant for the AU RNA (Fig 15D). This suggests that the 
stimulatory activity of the RNA adjuvants depends on several independent intracellular 
recognition pathways. 
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Figure 15. IRF activation, but not NF-κB activation, induced by RNA adjuvants can 
be inhibited by IRS-661 and IRS-954.  
To characterize the molecular targets responsible for recognizing the RNA adjuvants, THP-
1 Dual cells were pre-treated for 1 h with TLR inhibitors IRS-661, IRS-954, or chloroquine 
(CQ). Cells were then stimulated with RNA adjuvants or positive controls (GS-9620 or 
imiquimod). After 24 hours, cellular activation was interrogated. (A) IRF responses and 
(B) NF-κB responses for positive controls. (C) IRF responses and (D) NF-κB responses 
for RNA adjuvants. Results are representative of three independent experiments. Bars 
represent means ± SEM. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001 using unpaired 
Student’s t tests. 
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3.10 RNA adjuvants can be selectively packaged into HIV 
VLPs  
After characterizing the Multi, GU, and AU RNAs and their antigenicity in THP-1 Dual 
cell lines and in human PBMCs, we sought to determine whether these RNAs could be 
selectively packaged into HIV VLPs in place of HIV genomic RNA. To do this, HEK 293T 
cells were transfected with each packaging-competent RNA adjuvant. The following day, 
the same cells were transfected with the VLP-encoding vector, which had a deficient 
packaging signal. Cells were then incubated for 72 hours and adjuvanted VLPs were 
purified by ultracentrifugation (Fig 16A). Of note, the yields from adjuvanted VLPs are 
much lower than those of VLPs due to co-transfection of two plasmids as opposed to one.  
Before assessing whether the particles contained packaged RNA adjuvant, we ensured that 
the barcode sequences flanking the immunostimulatory regions could successfully be used 
for detection in a qRT-PCR assay as shown in the schematics in Fig 16B – D. To this 
extent, 100 ng of RNA adjuvant DNA vector was serially diluted 10-fold, and each dilution 
was assessed for its ability to be detected through qRT-PCR. The multi adjuvant remained 
detectable until 1 × 10,- ng dilution. A line of best fit across the mass of multi adjuvant 
DNA vector in each dilution had a goodness of fit measured at R2 = 0.96 (Fig 16B) when 
graphed against respective cycle threshold (Ct) values. The GU adjuvant remained 
detectable until 1 × 10,' ng dilution. The line of best fit across the mass of GU adjuvant 
DNA vector in each dilution of this adjuvant had a goodness of fit measured at R2 = 0.99 
(Fig 16C) when graphed against respective Ct values. Lastly, the AU adjuvant had the least 
sensitivity of detection and could only remain detectable until the 1 × 10,. ng dilution. 
The line of best fit across the mass of AU adjuvant DNA vector in each dilution for this 
adjuvant had a goodness of fit measured at R2 = 0.98 (Fig 16D) when graphed against 
respective Ct values.  
After verifying the ability of the RNA adjuvants to be detected by qRT-PCR and assessing 
their respective parameters of detection sensitivity, we sought to compare the amount of 
packaged RNA adjuvant in each of the adjuvanted VLPs. To this extent, RNA was 
extracted from adjuvanted VLPs and cDNA was synthesized. In parallel, the same process 
was carried out for HIV VLPs. We observed that the multi VLPs contained significantly 
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more multi RNA compared to HIV VLPs (Fig 16E). Similarly, AU VLPs contained 
significantly more AU RNA than HIV VLPs (Fig 16F). GU VLPs likewise contained 
significantly more GU RNA than HIV VLPs (Fig 16G). These results suggest that the 
delivery of RNA adjuvants can be selectively targeted by packaging into VLPs. 
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Figure 16. RNA adjuvants can be selectively packaged into HIV VLPs.  
To generate adjuvanted VLPs, HEK 293T cells were co-transfected with 5 µg/mL VLP-
encoding vector and 5 µg/mL RNA adjuvant-encoding vector. After incubating for 72 h at 
37 ˚C and 5% CO2, particles were purified from culture supernatant following 
ultracentrifugation (A). Viral RNA was extracted, and cDNA was synthesized, which was 
subsequently used in qRT-PCR reactions utilizing primers that bound specifically to 
individual RNA adjuvants shown in the colored arrows in B-D. The detection sensitivity 
of Multi RNA adjuvant (B), GUUC RNA adjuvant (C), and AUGU RNA adjuvant (D) was 
determined for qRT-PCR reactions. The amount of packaged RNA adjuvant was then 
determined using qRT-PCR and subsequently normalized to p24 (E-G). Results are 
representative of two independent experiments. Bars are depicted as means ± SEM. 
*p<0.05, **p<0.005 using paired Student’s t tests. 
 
3.11 Multi adjuvanted VLPs are more antigenic than HIV 
VLPs 
To determine whether adjuvanted VLPs were more antigenic than HIV VLPs, multi 
adjuvanted VLPs and HIV VLPs were generated as previously described. Briefly, HEK 
293T cells were co-transfected with a VLP-encoding vector and Multi RNA-encoding 
vector. HIV VLPs were generated by transfecting HEK 293T cells with VLP-encoding 
vector only. After 72 h, particles were isolated through ultracentrifugation. Subsequently, 
5 µg/mL of HIV VLP or 5 µg/mL of multi-adjuvanted VLP were co-cultured with either 
5 × 10' PBMC or THP-1 Dual cells in a 96-well plate format. In addition, THP-1 Dual 
cells and PBMCs were stimulated with 1X PMA/Iono as a positive control. After 24 hours, 
TNF-α concentration was determined in PBMC culture supernatant, whereas IRF 
activation was determined by measuring Lucia luciferase activity from THP-1 Dual cell 
culture supernatant. We observed that the multi adjuvanted VLPs induced significantly 
more TNF-α from PBMCs compared to HIV VLPs (Fig 17A). In addition, multi-
adjuvanted VLPs induced significantly more IRF activation in THP-1 Dual cells compared 
to HIV VLPs (Fig 17B). Collectively, this suggests that the packaged Multi-RNA adjuvant 
could induce greater cellular reactivation than HIV VLPs.  
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Figure 17. Multi Adjuvanted VLPs are more antigenic than HIV VLPs. 
To determine the antigenic difference between adjuvanted VLPs and HIV VLPs, we 
characterized IRF activation in THP-1 Dual cells, and TNF-α production in human PBMC 
(n = 2). Specifically, we compared the antigenicity of Multi adjuvanted VLPs to HIV VLPs. 
After culturing for 24 h, TNFα in PBMC culture supernatant was measured by ELISA (A). 
IRF activation was measured by Lucia luciferase activity in THP-1 culture supernatant (B). 
Bars are depicted as means ± SEM. *p<0.05, **p<0.005 using unpaired Student’s t tests.  
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Chapter 4 – Discussion  
4 Discussion  
Since the seminal discovery during the early 1980’s, that HIV-1 was the etiological agent 
behind the global AIDS pandemic, tens of millions of individuals have become infected 
and an almost equal number of individuals have succumbed to the opportunistic infections 
associated with the profound immuno-depletion. The introduction of antiretroviral therapy 
has transformed the landscape of the pandemic from one of a certain death sentence to a 
lifelong, treatment-manageable, chronic infection. However, there are several drawbacks 
with the current position of the HIV epidemic including: 1) the dangerous rise of cART 
resistant strains of HIV-1, beyond thresholds thought to be required to control HIV 
infection at the community level174,175; 2) the massive expansion of HIV-1 infection rates 
in numerous countries in Eastern Europe, Central Asia, and the Middle East (UNAIDS); 
3) the less than expected declines in new infections within test and treat communities in 
Africa176;  4) UNAIDS models predicting a rebound pandemic by 2030; 5) and the lack of 
an efficacious vaccine in the foreseeable future. These factors collectively paint a bleak 
forecast towards eradication efforts against HIV-1, or at the very least, efforts to control 
and reduce infection rates. Therefore, there is an urgent need for innovation in potential 
HIV-1 vaccine development that promotes long-lasting immunity for treatment of patients, 
or perhaps a line of therapeutic strategies to either control the HIV pandemic or cure HIV 
infected individuals.  
To date, the only effective countermeasure to HIV infection is the administration of a daily 
cART regimen, designed to block various stages of the HIV replication cycle. This daily 
regimen is a life-long treatment strategy that must be administered without interruption to 
prevent viral recrudescence and mitigate disease progression towards AIDS. The reason 
behind the inability of cART to effect a cure in treated individuals rests in the ability of the 
virus to, on rare occasions, reside in a dormant state within infected CD4 T cells. These 
latently infected cells are the source of recrudescing virus during treatment interruption and 
must be eliminated from the body in order to achieve a sterilizing cure. Over the last few 
years, our research team has focused on the development of a novel HIV VLP immuno-
therapeutic designed to target latently infected cells for reactivation. To our knowledge, 
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our group is the first to describe the targeted reactivation of the latent reservoir using HIV 
VLP quasi-species (manuscript in submission). This approach stemmed from several key 
findings in the literature that described the transcriptional reactivation of the latent 
reservoir, within CD4 T cells, through stimulation of cells with HIV antigens and/or 
peptides. Hence, we hypothesized that the latent reservoir might be preferentially housed 
in CD4+ T cells with TCR specificity for HIV epitopes. Subsequent work detailing the 
stimulation of CD4 T cells using VLP formulations, and how they led to latency reversal, 
are now the subject of a manuscript under peer review. These non-infectious, genomeless 
self-assembling nanoparticle structures, retains and expresses the native conformations 
encompassing the viral quasi-species from five infected individuals. While the initial 
previous work was carried out to investigate the potential latency reversing “shock” 
delivered by the VLP, ongoing work evaluating the ability of the repetitive geometry 
associated with repetitive ordered arrays of polypeptides that make up the constitution of 
the VLPs is now being evaluated for their unique ability to prime naïve immune responses, 
and also boost pre-existing immune responses in HIV-experienced individuals. This is 
being development within the context of both prophylactic and therapeutic vaccine 
strategies. The work presented in this thesis represents an alternative area of research 
involving VLPs, where adjuvanting RNAs were designed and tested for encapsulation 
within HIV particles. This was based on foundational work identifying HIV RNA as a 
potential proinflammatory factor in our in vitro assays, and data suggesting that co-
formulating VLP with exogenous excipients such as ssRNA could augment latency 
reversal. Therefore, we believe that the work presented is a significant step forward in the 
design of a second generation of immune-therapeutic VLPs, with greater potential for 
efficacious latency reversal and targeted immune activation.     
HIV VLPs are essentially viral shells lacking HIV genetic information. This absence of a 
viral genome renders the VLP non-infectious. We initially designed the latency reversal 
formulation as VLPs with an eye on downstream advancement towards human clinical 
trials. In that regard, the regulatory purity requirements by the European Medicines Agency 
(EMA) and World Health Organization (WHO) have strict guidelines on nucleic acid 
content in VLPs. For instance, a dose of 10ng DNA via the parenteral route or 100ug of 
DNA via the oral route is accepted177. Accordingly, as opposed to developing a viral 
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particle (VP) vaccine, which is easier and more cost effective, we developed VLPs to 
diminish nucleic acid incorporation in our vaccine. Initially this seemed advantageous 
when looking through the lens of a therapeutic vaccine for use in humans, as we would not 
require additional downstream processes such as BenzonaseÒ treatment. However, as it 
appears from the research presented in this thesis, in our attempt to develop a safe 
therapeutic, by removing the packaged viral RNA, we have inadvertently reduced the 
antigenicity and latency reversal properties of the HIV VLPs. The consequences of which 
we hypothesized to be a lack of critical PAMPs for stimulation of innate PRRs and 
subsequent production of pro-inflammatory mediators such as type-I interferons (T1 IFN) 
and TNF-α.  
To overcome these pitfalls associated with the reduced antigenicity and latency reversal of 
genomeless VLPs, we investigated methods to efficiently adjuvant our VLPs using RNA 
adjuvants. To do this we utilized a technology based on immunostimulatory, non-coding 
RNAs. The overall aim of this was to test the hypothesis that exogenous or VLP-packaged 
RNA can increase VLP antigenicity through intracellular recognition by cellular PRRs. If 
so, the eventual aim was to test the 2nd generation VLP formulations (i.e. VLPs + packaged 
RNA adjuvant) for their ability to augment HIV latency reversal. The work presented in 
this thesis provides clear evidence that TLR agonism can augment both HIV VLP 
antigenicity and the reversal of HIV latency in primary human cells. Initial screening of 
TLR agonists alone, such as Pam3CSK4 and Flagellin (which agonize TLR1/2 and TLR5, 
respectively) showed that latency reversal was achieved by Poly(I:C) (TLR3), Imiquimod 
(TLR7) and ssRNA (TLR7/8 agonist). In fact, the extent of latency reversal using soluble 
TLR ligands was found to comparable to latency reversal achieved by our latency reversing 
VLP formulation. Interestingly, we found that co-administration of exogenous ssRNA, a 
TLR7/8 ligand, with HIV VLPs was capable of augmenting latency reversal in primary 
human CD4+ T cells. Despite the elevation in latency reversal being non-statistically 
significant, we believe this additive effect to be a highly biologically significant result. This 
is because, we now understand that although our VLP formulation is a more potent latency 
reversal agent that clinically relevant HDACi and PKC agonists (manuscript under review), 
it may not be reactivating the full proviral reservoir. This is a crucial antecedent, as all 
activatable and replication competent HIV-1 must be purged from the body to achieve a 
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viable cure. Even a single intact and activatable provirus that persists post-treatment, 
increases the chance for viral recrudescence. Current estimates suggest that between 1 – 60 
CD4+ T cells/million may harbor replication competent virus178. The blood samples we 
have used in these studies are derived from donors, diagnosed and treated at acute stage of 
infection, and are therefore expected to have a very small reservoir. This greatly contrasts 
with the larger estimates of reservoir size in individuals treated at chronic stage of infection. 
Therefore, any increase in latency reversal in these acute patient samples are noteworthy 
as it signals more virus is being reactivated from what is a small reservoir.  
Several groups have previously explored the latency reversal potential of TLR ligands and 
provides context for the work presented in this thesis. For example, Novis et al. describe 
the latency reversal potential of Pam3CSK4, a TLR1/2 agonist, within an in vitro TCM 
cell culture model, and in cells isolated from aviremic HIV+ individuals. They suggest that 
the activation of TLR1/2 culminates in activation of several transcription factors such as 
NFAT, NF-κB, and AP-1, resulting in transactivation of proviral transcription. 
Additionally, TLR5 agonism using flagellin has also been characterized to induce latency 
reversal through the activation of NF-κB, resulting in viral gene expression in TCM cells 
isolated from aviremic individuals. Interestingly, recent work by Li et al., describe the role 
of toll-interacting protein (TOLLIP) on the maintenance of HIV latency. As a key cellular 
adaptor protein, TOLLIP functions to negatively regulate TLR signaling. Their work 
suggests that TOLLIP inhibits NF-κB-dependent transcription from the HIV-1 promotor 
and may therefore contribute to HIV latency. In fact, in a latently infected Jurkat CD4+ T 
cell model and CD4 TCM cells from infected individuals, TOLLIP knockdown promoted 
proviral transcription. In addition, other groups have found that TLR7/8 and TLR9 
activation can mediate latency reversal in a manner that is dependent on the production of 
T1 IFNs by plasmacytoid DCs (pDC). During infection, these pDCs function as antiviral 
sentinels, rapidly producing T1 IFNs in response to viral insults. This is mediated by viral 
RNA detection by TLR7/8, resulting in the recruitment of MyD88 using the adaptor protein 
AP3. Recruitment of MyD88 to endosomal compartments enables phosphorylation of 
IRF7, resulting in the downstream production of T1 IFNs. A clinical trial for GS-9620, a 
TLR7/8 agonist, is currently underway and previous studies in the non-human primate 
model has already generated evidence that correlates the use of GS-9620 with reductions 
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in viral reservoir size. In these NHP studies the animals showed strong upregulation of 
IFN-stimulated gene expression following GS-9620 administration along with blips in 
IFN-α within plasma within 24 h of administration. Hence, the ability of our RNA 
adjuvants to stimulate via TLR7/8, upregulate NF-kB and IRF as well as stimulate IFN-a 
production is noteworthy.   
Within this thesis, we also provide evidence here that suggests virally packaged HIV RNA 
is a significant contributor to HIV VP antigenicity and that the packaged RNA augments 
the latency reversal potency of HIV VPs. Therefore, we hypothesized that an engineered 
immunostimulatory RNA, capable of packaging into VLPs, may function to further 
enhance the latency reversal properties of the VLP formulations. Our rationale behind 
inclusion of a packaged RNA as opposed to the co-delivery of an adjuvanting RNA as an 
exogenous excipient in the VLP formulation, was the need for a specific and targeted 
approach to the latency reversal. We are cautious about using global immune cell 
activators, as there is a significant risk of non-specifically stimulating CD4+ T cells. In 
doing so, it would provide an abundance of target cells for which virus generated de novo 
can infect and reseed the reservoir. Furthermore, due to the inherent instability of RNA 
molecules, packaging an immunostimulatory RNA adjuvant into the protective HIV capsid 
could prevent its degradation before it has time to get to its intended destination. Since HIV 
can package its own genome using a stem-loop structure called the packaging element (Ψ), 
we designed immunostimulatory RNAs that leverages Ψ to facilitate the preferential 
packaging of the RNA adjuvants into HIV VLPs. This we hypothesized should enable the 
RNA adjuvants to outcompete the packaging of cellular RNAs and the RNAs associated 
with VLPs. The latter of which has an extensively mutated Ψ and has a significantly 
diminished ability to be package158. The adjuvants we have designed contains “GC”-rich 
motifs and “AU” rich motifs that have been previously shown to preferentially stimulate 
TLR7 and TLR8171. In these previous studies, “GU”-rich 4-mer sequences such as 
“GUUC” and “GUCC” were capable of potently activating TLR7/8 and IFN-α secretion, 
whereas “AU”-rich 4-mer sequences such as “AUGU” and “UAUU” were shown to be 
potent activators of TLR8 and TNF-α secretion. We therefore generated a Multi adjuvant 
that contained both “AU” and “GC”-rich domains, a single “GC”-rich adjuvant that 
promotes IFN-α responses, and a single “AU”-rich adjuvant to promote TNF-α responses. 
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Before encapsidating the RNAs into VLPs, which we believe would take a substantial 
amount of optimization, we condensed the candidate RNA adjuvants into lipoplexes to 
stimulate our reporter cell line and human PBMC. To do this, we incubated the RNAs with 
a polycationic lipid, DOTAP. This cationic lipid consists of a hydrophilic amine group 
connected to a hydrophobic carbon backbone through a biodegradable ester linker region, 
which greatly reduces associated toxicity due to its transient half-life in vivo. It is believed 
that DOTAP interacts strongly with RNA through electrostatic interactions between the 
hydrophilic trimethylammonium group and through hydrophobic interactions between the 
aliphatic carbon backbone and GC-rich regions of RNAs. Internalization of DOTAP-RNA 
complexes by cells has been shown to occur through several mechanisms, which include 
dynamin-dependent endocytosis via clathrin coated pits and non-specific dynamin-
independent endocytosis via macropinocytosis. Upon internalization and acidification of 
endolysosomal compartments of the cell containing DOTAP-RNA complexes, the 
interactions between the RNA and DOTAP molecules are overpowered by the reduction 
in local pH. As a result, the RNA is liberated from the DOTAP molecule and is free to 
activate cellular PRRs.   
By using lipoplexed RNAs we show data that corroborates findings from Forsbach et al., 
that “GC”-rich RNA adjuvants induced the highest amount of IFN-α production, whereas 
the “AU”-rich adjuvant induced the highest amount of TNF-α production in human 
PBMCs. Notably, we did not observe an additive effect of TNF-α and IFN-α production 
from the Multi adjuvant as a result of having both “AU”-rich and “GC”-rich sequences. 
We believe this is in part, due to differences in secondary structure and sizes of the RNAs, 
since the Multi adjuvant appeared to have shorter lengths of the immunostimulatory 
domains. However, the role of RNA length on antigenicity has been an area of contention 
because of the sequence length promiscuity of ORN binding sites in TLR7/8. However, 
other RNA-sensing PRRs have size preferences. For instance, Melanoma Differentiation-
Associated protein 5 (MDA5), a cytosolic RNA sensor, prefers longer sequences. This is 
because the RNA is used as a substrate to nucleate MDA5 filament formation. These 
filaments act as docking structures for the activation of mitochondrial antiviral-signaling 
protein (MAVS)179. In addition, the extensive secondary structure conferred by the 
repetitive sequence motifs may allow cytosolic detection of these RNA adjuvants by RIG-
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I. Interestingly, recent work has elucidated a family of short stem loop RNAs (SLR) that 
induces potent IFN responses through the specific activation of RIG-I. These SLRs are 
comprised of 10-14 nucleotides, and the minimal nature of these ligands suggest that 
multimerization of RIG-I on RNA is not required, unlike MDA5 which requires 
multimerization to promote MAVS signaling180. Therefore, it is plausible that a more 
careful examination of the size and secondary structures of adjuvanting RNAs could help 
define its immunostimulatory potential. In addition, studies evaluating the RNA adjuvants 
in knock-out mice will help implicate specific molecular pathways triggered by these 
RNAs.    
Since our engineered immunostimulatory RNAs displayed great promise as lipoplexed 
adjuvants, we also evaluated them as an exogenous adjuvant in our VLP formulations. As 
shown, the co-administration of our engineered adjuvants with VLPs did significantly 
increase the antigenicity of the VLPs in cell lines as measured by NF-κB and IRF 
activation. Our evidence also suggests that the exogenous RNA adjuvants increase the 
antigenicity of co-administered VLPs, to a greater extent than HIV RNA in VPs. To 
elucidate a mechanism through which the RNA adjuvants exert their antigenic effects, we 
used two ODNs (IRS-661 and IRS-954) that contain sequence motifs known to 
competitively inhibit TLR7 and 8 activation. Although the mechanism of inhibition by 
these ODNs are poorly understood, evidence based on the pattern of specificity suggest 
that the inhibition is mediated through competitive antagonism181. As an alternative to the 
ODNs, we also used chloroquine, which is a lysosomotropic compound that inhibits 
endosomal acidification. Unlike IRS-661 and 954, the mechanism of chloroquine is well-
characterized. Initially, chloroquine-mediated inhibition of endosomal acidification was 
thought to preclude TLR activation since a low endosomal pH was a key antecedent for 
endosomal TLR ligation and signaling182. However, there is now considerable evidence 
that suggests the underlying cause of inhibition is independent of endosomal acidification. 
Rather, the inhibitory effect of chloroquine stems from its high binding affinity to RNA. 
In doing so, chloroquine occludes moieties that normally confer binding to endosomal 
TLRs183. Our data shows that IRF activation can be inhibited by all three agents, whereas 
NF-κB activation could only be inhibited by chloroquine. The inability to attenuate NF-κB 
activation using IRS-661 and IRS-954 suggests that other innate immune recognition 
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pathways‒independent of endosomal TLRs‒are also being activated. Future studies must 
be conducted to further characterize the cross-talk across pathways of RNA recognition, 
because these details are still obscure.  
It is important to delineate the difference between the co-administration of exogenous RNA 
adjuvant and VLPs with the co-delivery of packaged RNA adjuvant in VLPs. This is 
because in the latter case, VLPs with encapsidated RNA are likely to both end up in the 
same endosomal compartment within the same cell. From a structural perspective, the 
former approach does not consolidate the RNA adjuvant and VLP into a single nanoparticle 
structure, whereas the latter approach utilizes ψ to package the RNA adjuvant inside the 
HIV VLP, ensuring that HIV VLP and RNA adjuvant is delivered to cells concurrently. 
Therefore, co-delivery does not guarantee the localization of the RNA adjuvant and HIV 
VLP to the same endosomal compartment, which is critical for enacting a durable immune 
response for maximal latency reversal potential. Several studies have shown that the 
“entrapment” of antigens into a single polymeric structure synergizes the antigenicity of 
its individual components by enabling the cross-presentation of antigens via MHC-I and 
MHC-II. In fact, this is one of the major reasons why conjugation of adjuvants and antigens, 
or adsorption of antigens onto adjuvants is done. Since the antigenicity of our RNA 
adjuvants were determined by co-administration of HIV VLP with a liposomal complex of 
exogenous RNA adjuvant, these results may underestimate the true antigenic capacity of 
the RNA adjuvants. We only administered the RNA adjuvant as an exogenous excipient in 
the VLP formulation to accelerate the investigative process by enabling us to quickly 
screen the candidate RNAs for their adjuvant activity. This also enabled us to avoid 
complications surrounding efficient production of VLPs containing packaged RNA using 
dual plasmid transfection methods.   
While the work outlined in the thesis emphasizes the importance of adjuvanting the VLPs 
in latency reversal studies, it also alludes to the natural ability of the HIV genome to trigger 
latency reversal. This was a surprise finding as HIV-1 is thought to be “hardwired” to form 
a transcriptionally silent, latent reservoir within cells, with what has been previously 
described as a virally-encoded program behind the latency109. Moreover, Brodin et al., has 
recently shown that within infected individuals, the virus that was replicating immeditaley 
prior to suppressive cART may be the virus that predominates within the HIV-1 DNA 
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reservoir184, while Abrahams et al., show that the replication-competent latent reservoir is 
primarily established near the time of cART initiation185. Of course these are important 
points of discussion which cannot be easily answered within the scope of this thesis. 
In summary, the work presented in this thesis offers evidence that implicates exogenous 
or virally packaged RNA in enhancing VLP antigenicity and latency reversal ability. In 
light of this, we also describe the engineering of immunostimulatory RNAs that can be 
packaged into VLPs and further augment antigenicity.  
49 
 
Bibliography  
1. Gallo, R. et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-
III) from patients with AIDS and at risk for AIDS. Science (80-. ). 224, 500–503 
(1984). 
2. Françoise Barré-Sinoussi and Luc Montagnier share the 2008 Nobel Prize for 
Physiology and Medicine for their discovery of the human immunodeficiency 
virus (HIV). AIDS 23, 1 (2009). 
3. Barré-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at 
risk for acquired immune deficiency syndrome (AIDS). Rev. Investig. Clin. 56, 
126–129 (2004). 
4. Vidal, N. et al. Unprecedented degree of human immunodeficiency virus type 1 
(HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests 
that the HIV-1 pandemic originated in Central Africa. J. Virol. 74, 10498–507 
(2000). 
5. Zhu, T. et al. An African HIV-1 sequence from 1959 and implications for the 
origin of the epidemic. Nature 391, 594–597 (1998). 
6. Sharp, P. M. & Hahn, B. H. The evolution of HIV-1 and the origin of AIDS. 
doi:10.1098/rstb.2010.0031 
7. Hahn, B. H., Shaw, G. M., De Cock, K. M. & Sharp, P. M. AIDS as a Zoonosis: 
Scientific and Public Health Implications. Science (80-. ). 287, 607–614 (2000). 
8. Worobey, M. et al. Island Biogeography Reveals the Deep History of SIV. Science 
(80-. ). 329, 1487–1487 (2010). 
9. The acquired immune deficiency syndrome (AIDS)--a multidisciplinary enigma. 
West. J. Med. 140, 66–81 (1984). 
10. Hemelaar, J. The origin and diversity of the HIV-1 pandemic. Trends Mol. Med. 
18, 182–192 (2012). 
50 
 
11. Joseph, S. B., Swanstrom, R., Kashuba, A. D. M. & Cohen, M. S. Bottlenecks in 
HIV-1 transmission: insights from the study of founder viruses. Nat. Rev. 
Microbiol. 13, 414–25 (2015). 
12. Bonhoeffer, S., Holmes, E. C. & Nowak, M. A. Causes of HIV diversity. Nature 
376, 125–125 (1995). 
13. Smyth, R. P., Davenport, M. P. & Mak, J. The origin of genetic diversity in HIV-1. 
Virus Res. 169, 415–429 (2012). 
14. Peeters, M., Jung, M. & Ayouba, A. The origin and molecular epidemiology of 
HIV. Expert Rev. Anti. Infect. Ther. 11, 885–896 (2013). 
15. Ngcapu, S. et al. Characterization of Nucleoside Reverse Transcriptase Inhibitor-
Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected 
Individuals. Viruses 9, 330 (2017). 
16. Sivay, M. V. et al. HIV-1 diversity among young women in rural South Africa: 
HPTN 068. PLoS One 13, e0198999 (2018). 
17. Billings, E. et al. HIV-1 Genetic Diversity Among Incident Infections in Mbeya, 
Tanzania. AIDS Res. Hum. Retroviruses 33, 373–381 (2017). 
18. Gounder, K. et al. Complex Subtype Diversity of HIV-1 Among Drug Users in 
Major Kenyan Cities. AIDS Res. Hum. Retroviruses 33, 500–510 (2017). 
19. Nii-Trebi, N. I. et al. Dynamic HIV-1 genetic recombination and genotypic drug 
resistance among treatment-experienced adults in northern Ghana. J. Med. 
Microbiol. 66, 1663–1672 (2017). 
20. Castley, A. et al. A national study of the molecular epidemiology of HIV-1 in 
Australia 2005–2012. PLoS One 12, e0170601 (2017). 
21. Oster, A. M. et al. Increasing HIV-1 subtype diversity in seven states, United 
States, 2006–2013. Ann. Epidemiol. 27, 244-251.e1 (2017). 
51 
 
22. Volz, E. M. et al. Molecular Epidemiology of HIV-1 Subtype B Reveals 
Heterogeneous Transmission Risk: Implications for Intervention and Control. J. 
Infect. Dis. 217, 1522–1529 (2018). 
23. Avanzi, V. M. et al. Profile of HIV subtypes in HIV/HBV- and HIV/HCV-
coinfected patients in Southern Brazil. Rev. Soc. Bras. Med. Trop. 50, 470–477 
(2017). 
24. Li, K. et al. Near Full-Length Genomic Characterization of a Novel HIV Type 1 
Recombinant Form (CRF01_AE/B) Identified from Anhui, China. AIDS Res. 
Hum. Retroviruses (2018). doi:10.1089/AID.2018.0144 
25. Aibekova, L. et al. Molecular epidemiology of HIV-1 subtype A in former Soviet 
Union countries. PLoS One 13, e0191891 (2018). 
26. Sharma, A. L., Singh, T. R., Devi, K. R. & Singh, L. S. Molecular epidemiology of 
HIV-1 among the HIV infected people of Manipur, Northeastern India: Emergence 
of unique recombinant forms. J. Med. Virol. 89, 989–999 (2017). 
27. Hemelaar, J. et al. Global and regional molecular epidemiology of HIV-1, 1990–
2015: a systematic review, global survey, and trend analysis. Lancet Infect. Dis. 
19, 143–155 (2019). 
28. Shaw, G. M. & Hunter, E. HIV transmission. Cold Spring Harb. Perspect. Med. 2, 
(2012). 
29. Shaw, G. M. & Hunter, E. HIV transmission. Cold Spring Harb. Perspect. Med. 2, 
(2012). 
30. Mushahwar, I. K. Human Immunodeficiency Viruses: Molecular Virology, 
Pathogenesis, Diagnosis and Treatment. in 75–87 (2006). doi:10.1016/S0168-
7069(06)13005-0 
31. Baldwin, D. N. & Linial, M. L. The roles of Pol and Env in the assembly pathway 
of human foamy virus. J. Virol. (1998). 
52 
 
32. Freed, E. O. HIV-1 Gag proteins: Diverse functions in the virus life cycle. 
Virology 251, 1–15 (1998). 
33. Bernacchi, S. et al. HIV-1 nucleocapsid protein activates transient melting of least 
stable parts of the secondary structure of TAR and its complementary sequence. J. 
Mol. Biol. 317, 385–399 (2002). 
34. German Advisory Committee Blood (Arbeitskreis Blut), Subgroup ‘Assessment of 
Pathogens Transmissible by Blood’, G. A. C. B. (Arbeitskreis & Blood’, S. 
‘Assessment of P. T. by. Human Immunodeficiency Virus (HIV). Transfus. Med. 
Hemother. 43, 203–22 (2016). 
35. Malim, M. H. & Emerman, M. HIV-1 Accessory Proteins—Ensuring Viral 
Survival in a Hostile Environment. Cell Host Microbe 3, 388–398 (2008). 
36. Merk, A. & Subramaniam, S. HIV-1 envelope glycoprotein structure. Curr. Opin. 
Struct. Biol. 23, 268–276 (2013). 
37. Turner, B. G. & Summers, M. F. Structural biology of HIV 1 1Edited by P. E. 
Wright. J. Mol. Biol. 285, 1–32 (1999). 
38. Hergott, C. B. et al. Zinc finger function of HIV-1 nucleocapsid protein is required 
for removal of 5′-terminal genomic RNA fragments: A paradigm for RNA removal 
reactions in HIV-1 reverse transcription. Virus Res. 171, 346–355 (2013). 
39. Rein, A. RNA Packaging in HIV. Trends Microbiol. 27, 715–723 (2019). 
40. Goff, S. P. et al. Dissection of specific binding of HIV-1 Gag to the ‘packaging 
signal’ in viral RNA. (2017). doi:10.7554/eLife.27055.001 
41. Webb, J. A., Jones, C. P., Parent, L. J., Rouzina, I. & Musier-Forsyth, K. Distinct 
binding interactions of HIV-1 Gag to Psi and non-Psi RNAs: implications for viral 
genomic RNA packaging. RNA 19, 1078–88 (2013). 
42. Sinha, S. & Grandgenett, D. P. Recombinant Human Immunodeficiency Virus 
Type 1 Integrase Exhibits a Capacity for Full-Site Integration In Vitro That Is 
53 
 
Comparable to That of Purified Preintegration Complexes from Virus-Infected 
Cells. J. Virol. 79, 8208–8216 (2005). 
43. Engelman, A., Mizuuchi, K. & Craigie, R. HIV-1 DNA integration: mechanism of 
viral DNA cleavage and DNA strand transfer. Cell 67, 1211–21 (1991). 
44. Delelis, O., Carayon, K., Saïb, A., Deprez, E. & Mouscadet, J.-F. Integrase and 
integration: biochemical activities of HIV-1 integrase. Retrovirology 5, 114 
(2008). 
45. Mbondji-wonje, C. et al. Distinctive variation in the U3R region of the 5’ Long 
Terminal Repeat from diverse HIV-1 strains. PLoS One 13, e0195661 (2018). 
46. Mbonye, U. & Karn, J. Transcriptional control of HIV latency: Cellular signaling 
pathways, epigenetics, happenstance and the hope for a cure. Virology 0, 328 
(2014). 
47. Donahue, D. A. & Wainberg, M. A. Cellular and molecular mechanisms involved 
in the establishment of HIV-1 latency. Retrovirology 10, 11 (2013). 
48. Krebs, F. C., Hogan, T. H., Quiterio, S., Gartner, S. & Wigdahl, B. Lentiviral LTR-
directed Expression, Sequence Variation, and Disease Pathogenesis. 
49. Gornalusse, G. G. et al. Epigenetic mechanisms, T-cell activation, and CCR5 
genetics interact to regulate T-cell expression of CCR5, the major HIV-1 
coreceptor. Proc. Natl. Acad. Sci. 112, E4762–E4771 (2015). 
50. Bleul, C. C., Wu, L., Hoxie, J. A., Springer, T. A. & Mackay, C. R. The HIV 
coreceptors CXCR4 and CCR5 are differentially expressed and regulated on 
human T lymphocytes. Proc. Natl. Acad. Sci. 94, 1925–1930 (1997). 
51. Klein, K. et al. Higher sequence diversity in the vaginal tract than in blood at early 
HIV-1 infection. PLoS Pathog. (2018). doi:10.1371/journal.ppat.1006754 
52. Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in 
rhesus monkeys. Nature 512, 74–7 (2014). 
54 
 
53. Singh, B., Schwartz, J. A., Sandrock, C., Bellemore, S. M. & Nikoopour, E. 
Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T 
helper (Th17) cells. Indian J. Med. Res. 138, 591–4 (2013). 
54. Sufiawati, I. & Tugizov, S. M. HIV-Associated Disruption of Tight and Adherens 
Junctions of Oral Epithelial Cells Facilitates HSV-1 Infection and Spread. PLoS 
One 9, e88803 (2014). 
55. Tugizov, S. M. et al. HIV-associated disruption of mucosal epithelium facilitates 
paracellular penetration by human papillomavirus. Virology 446, 378–388 (2013). 
56. Ferreira, V. H., Nazli, A., Dizzell, S. E., Mueller, K. & Kaushic, C. The Anti-
Inflammatory Activity of Curcumin Protects the Genital Mucosal Epithelial 
Barrier from Disruption and Blocks Replication of HIV-1 and HSV-2. PLoS One 
10, e0124903 (2015). 
57. Zhong, Y. et al. Caveolin-1 regulates human immunodeficiency virus-1 Tat-
induced alterations of tight junction protein expression via modulation of the ras 
signaling. J. Neurosci. 28, 7788–7796 (2008). 
58. Nazli, A. et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier 
integrity allowing microbial translocation. PLoS Pathog. 6, e1000852 (2010). 
59. Sufiawati, I. & Tugizov, S. M. HIV-induced matrix metalloproteinase-9 activation 
through mitogen-activated protein kinase signalling promotes HSV-1 cell-to-cell 
spread in oral epithelial cells. J. Gen. Virol. 99, 937–947 (2018). 
60. Gao, Y., McKay, P. F. & Mann, J. F. S. Advances in HIV-1 vaccine development. 
Viruses (2018). doi:10.3390/v10040167 
61. Biancotto, A. et al. HIV-1 induced activation of CD4+ T cells creates new targets 
for HIV-1 infection in human lymphoid tissue ex vivo. Blood 111, 699–704 
(2008). 
62. Doitsh, G. et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 
infection. Nature 505, 509–514 (2014). 
55 
 
63. Lawlor, K. E., Conos, S. & Vince, J. E. Pyroptosis. in Apoptosis and Beyond: The 
Many Ways Cells Die 26, 317–341 (2018). 
64. Knoblich, K. et al. The human lymph node microenvironment unilaterally 
regulates T-cell activation and differentiation. PLoS Biol. 16, e2005046 (2018). 
65. Myszka, D. G. et al. Energetics of the HIV gp120-CD4 binding reaction. Proc. 
Natl. Acad. Sci. U. S. A. 97, 9026–31 (2000). 
66. Lai, A. L. & Freed, J. H. HIV gp41 fusion peptide increases membrane ordering in 
a cholesterol-dependent fashion. Biophys. J. 106, 172–81 (2014). 
67. Campbell, E. M. & Hope, T. J. HIV-1 capsid: the multifaceted key player in HIV-1 
infection. Nat. Rev. Microbiol. 13, 471–83 (2015). 
68. Pornillos, O., Ganser-Pornillos, B. K. & Yeager, M. Atomic-level modelling of the 
HIV capsid. Nature 469, 424–427 (2011). 
69. Márquez, C. L. et al. Kinetics of HIV-1 capsid uncoating revealed by single-
molecule analysis. Elife 7, (2018). 
70. Arhel, N. Revisiting HIV-1 uncoating. Retrovirology 7, 96 (2010). 
71. Lelek, M. et al. Superresolution imaging of HIV in infected cells with FlAsH-
PALM. doi:10.1073/pnas.1013267109/-/DCSupplemental 
72. Miller, M. D. et al. Human immunodeficiency virus type 1 preintegration 
complexes: studies of organization and composition. J. Virol. 71, 5382–90 (1997). 
73. Hu, W.-S. & Hughes, S. H. HIV-1 reverse transcription. Cold Spring Harb. 
Perspect. Med. 2, (2012). 
74. Jayappa, K. D., Ao, Z. & Yao, X. The HIV-1 passage from cytoplasm to nucleus: 
the process involving a complex exchange between the components of HIV-1 and 
cellular machinery to access nucleus and successful integration. Int. J. Biochem. 
Mol. Biol. 3, 70–85 (2012). 
56 
 
75. Schaller, T. et al. HIV-1 Capsid-Cyclophilin Interactions Determine Nuclear 
Import Pathway, Integration Targeting and Replication Efficiency. PLoS Pathog. 
7, e1002439 (2011). 
76. Achuthan, V. et al. Capsid-CPSF6 Interaction Licenses Nuclear HIV-1 Trafficking 
to Sites of Viral DNA Integration. Cell Host Microbe 24, 392-404.e8 (2018). 
77. Bejarano, D. A. et al. HIV-1 nuclear import in macrophages is regulated by 
CPSF6-capsid interactions at the nuclear pore complex. Elife 8, (2019). 
78. Arhel, N. Revisiting HIV-1 uncoating. Retrovirology 7, 96 (2010). 
79. Richetta, C. et al. Two-long terminal repeat (LTR) DNA circles are a substrate for 
HIV-1 integrase. J. Biol. Chem. 294, 8286–8295 (2019). 
80. Sloan, R. D. & Wainberg, M. A. The role of unintegrated DNA in HIV infection. 
Retrovirology 8, 52 (2011). 
81. Konsavage, W. M., Sudol, M. & Katzman, M. Effects of varying the spacing 
within the D,D-35-E motif in the catalytic region of retroviral integrase. Virology 
379, 223–233 (2008). 
82. Šenigl, F., Miklík, D., Auxt, M. & Hejnar, J. Accumulation of long-term 
transcriptionally active integrated retroviral vectors in active promoters and 
enhancers. Nucleic Acids Res. 45, 12752–12765 (2017). 
83. Schröder, A. R. W. et al. HIV-1 integration in the human genome favors active 
genes and local hotspots. Cell 110, 521–9 (2002). 
84. Cesana, D. et al. HIV-1-mediated insertional activation of STAT5B and BACH2 
trigger viral reservoir in T regulatory cells. Nat. Commun. 8, 498 (2017). 
85. Delannoy, A., Poirier, M. & Bell, B. Cat and Mouse: HIV Transcription in 
Latency, Immune Evasion and Cure/Remission Strategies. Viruses 11, 269 (2019). 
86. Engelman, A. & Cherepanov, P. The Lentiviral Integrase Binding Protein 
57 
 
LEDGF/p75 and HIV-1 Replication. PLoS Pathog. 4, e1000046 (2008). 
87. Ferris, A. L. et al. Lens epithelium-derived growth factor fusion proteins redirect 
HIV-1 DNA integration. Proc. Natl. Acad. Sci. U. S. A. 107, 3135–40 (2010). 
88. Le Rouzic, E. et al. Dual inhibition of HIV-1 replication by integrase-LEDGF 
allosteric inhibitors is predominant at the post-integration stage. Retrovirology 10, 
144 (2013). 
89. Sowd, G. A. et al. A critical role for alternative polyadenylation factor CPSF6 in 
targeting HIV-1 integration to transcriptionally active chromatin. Proc. Natl. Acad. 
Sci. 113, E1054–E1063 (2016). 
90. Van de Vosse, D. W., Wan, Y., Wozniak, R. W. & Aitchison, J. D. Role of the 
nuclear envelope in genome organization and gene expression. Wiley Interdiscip. 
Rev. Syst. Biol. Med. 3, 147–66 (2011). 
91. Puray-Chavez, M. et al. Multiplex single-cell visualization of nucleic acids and 
protein during HIV infection. Nat. Commun. 8, 1882 (2017). 
92. Leblanc, J., Weil, J. & Beemon, K. Posttranscriptional regulation of retroviral gene 
expression: primary RNA transcripts play three roles as pre-mRNA, mRNA, and 
genomic RNA. Wiley Interdiscip. Rev. RNA 4, 567–80 (2013). 
93. Mann, J. K. et al. Nef-mediated down-regulation of CD4 and HLA class I in HIV-
1 subtype C infection: association with disease progression and influence of 
immune pressure. Virology 0, 214 (2014). 
94. Moir, S., Chun, T.-W. & Fauci, A. S. Pathogenic Mechanisms of HIV Disease. 
Annu. Rev. Pathol. Mech. Dis. 6, 223–248 (2011). 
95. McMichael, A. J. & Rowland-Jones, S. L. Cellular immune responses to HIV. 
Nature 410, 980–987 (2001). 
96. Evans, V. A. et al. Programmed cell death-1 contributes to the establishment and 
maintenance of HIV-1 latency. AIDS 32, 1491–1497 (2018). 
58 
 
97. Grabmeier-Pfistershammer, K. et al. Antibodies targeting BTLA or TIM-3 
enhance HIV-1 specific T cell responses in combination with PD-1 blockade. Clin. 
Immunol. 183, 167–173 (2017). 
98. Boyer, Z. & Palmer, S. Targeting Immune Checkpoint Molecules to Eliminate 
Latent HIV. Front. Immunol. 9, 2339 (2018). 
99. Boasso, A., Shearer, G. M. & Chougnet, C. Immune dysregulation in human 
immunodeficiency virus infection: know it, fix it, prevent it? J. Intern. Med. 265, 
78–96 (2009). 
100. Nagase, H. et al. Mechanism of Hypergammaglobulinemia by HIV Infection: 
Circulating Memory B-Cell Reduction with Plasmacytosis. Clin. Immunol. 100, 
250–259 (2001). 
101. De Milito, A. et al. Mechanisms of hypergammaglobulinemia and impaired 
antigen-specific humoral immunity in HIV-1 infection. Blood 103, 2180–6 (2004). 
102. Szakal, A. K. & Tew, J. G. Significance of iccosomes in the germinal centre 
reaction. in Research in Immunology (1991). doi:10.1016/0923-2494(91)90072-Q 
103. Kohler, H., Goudsmit, J. & Nara, P. Clonal dominance: Cause for a limited and 
failing immune response to HIV-1 infection and vaccination. J. Acquir. Immune 
Defic. Syndr. (1992). 
104. Zanoni, B. C. & Gandhi, R. T. Update on opportunistic infections in the era of 
effective antiretroviral therapy. Infect. Dis. Clin. North Am. 28, 501–18 (2014). 
105. Pirrone, V., Thakkar, N., Jacobson, J. M., Wigdahl, B. & Krebs, F. C. 
Combinatorial approaches to the prevention and treatment of HIV-1 infection. 
Antimicrob. Agents Chemother. 55, 1831–42 (2011). 
106. May, M. T. et al. Impact on life expectancy of HIV-1 positive individuals of 
CD4R cell count and viral load response to antiretroviral therapy. AIDS (2014). 
doi:10.1097/QAD.0000000000000243 
59 
 
107. Ogunbodede, E. O. HIV/AIDS situation in Africa. Int. Dent. J. 54, 352–60 (2004). 
108. Granich, R., Williams, B. & Montaner, J. Fifteen million people on antiretroviral 
treatment by 2015. Curr. Opin. HIV AIDS 8, 41–49 (2013). 
109. Razooky, B. S., Pai, A., Aull, K., Rouzine, I. M. & Weinberger, L. S. A Hardwired 
HIV Latency Program. Cell 160, 990–1001 (2015). 
110. Rouzine, I. M., Weinberger, A. D. & Weinberger, L. S. An Evolutionary Role for 
HIV Latency in Enhancing Viral Transmission. Cell 160, 1002–1012 (2015). 
111. Pan, X., Baldauf, H.-M., Keppler, O. T. & Fackler, O. T. Restrictions to HIV-1 
replication in resting CD4+ T lymphocytes. Cell Res. 23, 876–885 (2013). 
112. Amie, S. M., Noble, E. & Kim, B. Intracellular nucleotide levels and the control of 
retroviral infections. Virology 436, 247–254 (2013). 
113. Kennedy, E. M. et al. Ribonucleoside Triphosphates as Substrate of Human 
Immunodeficiency Virus Type 1 Reverse Transcriptase in Human Macrophages. J. 
Biol. Chem. 285, 39380–39391 (2010). 
114. Doitsh, G. & Greene, W. C. Dissecting How CD4 T Cells Are Lost During HIV 
Infection. Cell Host Microbe 19, 280–91 (2016). 
115. Lusic, M., Marcello, A., Cereseto, A. & Giacca, M. Regulation of HIV-1 gene 
expression by histone acetylation and factor recruitment at the LTR promoter. 
EMBO J. 22, 6550–61 (2003). 
116. Ping, Y.-H. & Rana, T. M. DSIF and NELF Interact with RNA Polymerase II 
Elongation Complex and HIV-1 Tat Stimulates P-TEFb-mediated Phosphorylation 
of RNA Polymerase II and DSIF during Transcription Elongation. J. Biol. Chem. 
276, 12951–12958 (2001). 
117. Morton, E. L., Forst, C. V, Zheng, Y., Depaula-Silva, A. B. & Ramirez, N.-G. P. 
Transcriptional Circuit Fragility Influences HIV Proviral Fate. (2019). 
doi:10.1016/j.celrep.2019.03.007 
60 
 
118. Sarracino, A. et al. Posttranscriptional Regulation of HIV-1 Gene Expression 
during Replication and Reactivation from Latency by Nuclear Matrix Protein 
MATR3. MBio 9, (2018). 
119. Zhou, M. et al. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the 
RNA polymerase II carboxyl-terminal domain during human immunodeficiency 
virus type 1 transcription. Mol. Cell. Biol. 20, 5077–86 (2000). 
120. Siliciano, R. F. & Greene, W. C. HIV latency. Cold Spring Harb. Perspect. Med. 
(2011). doi:10.1101/cshperspect.a007096 
121. Chun, T.-W., Davey, R. T., Engel, D., Lane, H. C. & Fauci, A. S. Re-emergence of 
HIV after stopping therapy. Nature 401, 874–875 (1999). 
122. Davey, R. T. et al. HIV-1 and T cell dynamics after interruption of highly active 
antiretroviral therapy (HAART) in patients with a history of sustained viral 
suppression. Proc. Natl. Acad. Sci. 96, 15109–15114 (1999). 
123. Dahabieh, M. S., Battivelli, E. & Verdin, E. Understanding HIV Latency: The 
Road to an HIV Cure. Annu. Rev. Med. (2015). doi:10.1146/annurev-med-092112-
152941 
124. Rocco, J., Mellors, J. W. & Macatangay, B. J. Regulatory T cells: the ultimate HIV 
reservoir? J. virus Erad. 4, 209–214 (2018). 
125. Ananworanich, J. et al. HIV DNA Set Point is Rapidly Established in Acute HIV 
Infection and Dramatically Reduced by Early ART. EBioMedicine 11, 68–72 
(2016). 
126. Ananworanich, J., Dubé, K. & Chomont, N. How does the timing of antiretroviral 
therapy initiation in acute infection affect HIV reservoirs? Curr. Opin. HIV AIDS 
10, 18–28 (2015). 
127. Steingrover, R. et al. HIV-1 viral rebound dynamics after a single treatment 
interruption depends on time of initiation of highly active antiretroviral therapy. 
AIDS 22, 1583–1588 (2008). 
61 
 
128. Ganusov, V. V et al. Fitness costs and diversity of the cytotoxic T lymphocyte 
(CTL) response determine the rate of CTL escape during acute and chronic phases 
of HIV infection. J. Virol. 85, 10518–28 (2011). 
129. Steingrover, R. et al. HIV-1 viral rebound dynamics after a single treatment 
interruption depends on time of initiation of highly active antiretroviral therapy. 
AIDS 22, 1583–1588 (2008). 
130. Liu, C., Ma, X., Liu, B., Chen, C. & Zhang, H. HIV-1 functional cure: Will the 
dream come true? BMC Med. (2015). doi:10.1186/s12916-015-0517-y 
131. Deeks, S. G. HIV: Shock and kill. Nature (2012). doi:10.1038/487439a 
132. Beliakova-Bethell, N. et al. Relative efficacy of T cell stimuli as inducers of 
productive HIV-1 replication in latently infected CD4 lymphocytes from patients 
on suppressive cART. Virology (2017). doi:10.1016/j.virol.2017.05.008 
133. Sanyal, A. et al. Novel assay reveals a large, inducible, replication-competent 
HIV-1 reservoir in resting CD4+ T cells. Nat. Med. (2017). doi:10.1038/nm.4347 
134. Spivak, A. M. & Planelles, V. Novel Latency Reversal Agents for HIV-1 Cure. 
Annu. Rev. Med. 69, 421–436 (2018). 
135. Jiang, G. & Dandekar, S. Targeting NF-κB signaling with protein kinase C 
agonists as an emerging strategy for combating HIV latency. AIDS Res. Hum. 
Retroviruses 31, 4–12 (2015). 
136. Novis, C. L. et al. Reactivation of latent HIV-1 in central memory CD4+ T cells 
through TLR-1/2 stimulation. Retrovirology 10, 119 (2013). 
137. Thibault, S., Imbeault, M., Tardif, M. R. & Tremblay, M. J. TLR5 stimulation is 
sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and 
activate virus gene expression in central memory CD4+ T cells. Virology 389, 20–
25 (2009). 
138. Alvarez-Carbonell, D. et al. Toll-like receptor 3 activation selectively reverses 
62 
 
HIV latency in microglial cells. Retrovirology 14, 9 (2017). 
139. Offersen, R. et al. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances 
HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected 
Autologous CD4+ T Cells. J. Virol. 90, 4441–4453 (2016). 
140. Lim, S. Y. et al. TLR7 agonists induce transient viremia and reduce the viral 
reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Sci. Transl. 
Med. (2018). doi:10.1126/scitranslmed.aao4521 
141. Rasmussen, T. A. et al. Comparison of HDAC inhibitors in clinical development: 
Effect on HIV production in latently infected cells and T-cell activation. Hum. 
Vaccines Immunother. (2013). doi:10.4161/hv.23800 
142. Elliott, J. H. et al. Activation of HIV Transcription with Short-Course Vorinostat 
in HIV-Infected Patients on Suppressive Antiretroviral Therapy. PLoS Pathog. 
(2014). doi:10.1371/journal.ppat.1004473 
143. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients 
on antiretroviral therapy. Nature (2012). doi:10.1038/nature11286 
144. Sengupta, S. & Siliciano, R. F. Targeting the Latent Reservoir for HIV-1. 
Immunity (2018). doi:10.1016/j.immuni.2018.04.030 
145. New, M., Olzscha, H. & La Thangue, N. B. HDAC inhibitor-based therapies: Can 
we interpret the code? Molecular Oncology (2012). 
doi:10.1016/j.molonc.2012.09.003 
146. Jones, R. B. et al. Histone deacetylase inhibitors impair the elimination of hiv-
infected cells by cytotoxic t-lymphocytes. PLoS Pathog. (2014). 
doi:10.1371/journal.ppat.1004287 
147. Descours, B. et al. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring 
replication-competent proviruses. Nature 543, 564–567 (2017). 
148. Osuna, C. E. et al. Evidence that CD32a does not mark the HIV-1 latent reservoir. 
63 
 
Nature 561, E20–E28 (2018). 
149. Demoustier, A. et al. In patients on prolonged HAART, a significant pool of HIV 
infected CD4 T cells are HIV-specific. AIDS 16, 1749–1754 (2002). 
150. Douek, D. C. et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 
417, 95–98 (2002). 
151. Hunt, P. W. et al. HIV-specific CD4+ T cells may contribute to viral persistence in 
HIV controllers. Clin. Infect. Dis. (2011). doi:10.1093/cid/ciq202 
152. Moris, A. et al. Dendritic cells and HIV-specific CD4+ T cells: HIV antigen 
presentation, T-cell activation, and viral transfer. Blood (2006). doi:10.1182/blood-
2006-02-006361 
153. Ranasinghe, S. et al. HIV-Specific CD4 T Cell Responses to Different Viral 
Proteins Have Discordant Associations with Viral Load and Clinical Outcome. J. 
Virol. (2012). doi:10.1128/jvi.05577-11 
154. Gao, Y., Wijewardhana, C. & Mann, J. F. S. Virus-like particle, liposome, and 
polymeric particle-based vaccines against HIV-1. Frontiers in Immunology (2018). 
doi:10.3389/fimmu.2018.00345 
155. Faridi, R., Zahra, A., Khan, K. & Idrees, M. Oncogenic potential of Human 
Papillomavirus (HPV) and its relation with cervical cancer. Virol. J. 8, 269 (2011). 
156. Lu, W., Wu, X., Lu, Y., Guo, W. & Andrieu, J. M. Therapeutic dendritic-cell 
vaccine for simian aids. Nat. Med. (2003). doi:10.1038/nm806 
157. Lu, W., Arraes, L. C., Ferreira, W. T. & Andrieu, J. M. Therapeutic dendritic-cell 
vaccine for chronic HIV-1 infection. Nat. Med. (2004). doi:10.1038/nm1147 
158. Pankrac, J. et al. A heterogeneous human immunodeficiency virus-like particle 
(VLP) formulation produced by a novel vector system. npj Vaccines (2018). 
doi:10.1038/s41541-017-0040-6 
64 
 
159. Dudley, D. M. et al. A novel yeast-based recombination method to clone and 
propagate diverse HIV-1 isolates. Biotechniques (2009). doi:10.2144/000113119 
160. Nair, S., Archer, G. E. & Tedder, T. F. Isolation and generation of human dendritic 
cells. Curr. Protoc. Immunol. (2012). doi:10.1002/0471142735.im0732s99 
161. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral 
load in HIV-1 infection. Nature (1997). doi:10.1038/387183a0 
162. Shete, A. et al. Short Communication: HIV Antigen-Specific Reactivation of HIV 
Infection from Cellular Reservoirs: Implications in the Settings of Therapeutic 
Vaccinations. AIDS Res. Hum. Retroviruses 28, 835–843 (2011). 
163. Tsai, A. et al. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and 
HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive 
Antiretroviral Therapy. J. Virol. 91, (2017). 
164. Macedo, A. B. et al. Dual TLR2 and TLR7 agonists as HIV latency-reversing 
agents. JCI insight 3, (2018). 
165. Junt, T. & Barchet, W. Translating nucleic acid-sensing pathways into therapies. 
Nature Reviews Immunology (2015). doi:10.1038/nri3875 
166. Søgaard, O. S. et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In 
Vivo. PLoS Pathog. (2015). doi:10.1371/journal.ppat.1005142 
167. Schlaepfer, E. & Speck, R. F.                     TLR8 Activates HIV from Latently 
Infected Cells of Myeloid-Monocytic Origin Directly via the MAPK Pathway and 
from Latently Infected CD4                    +                    T Cells Indirectly via TNF-α                  
. J. Immunol. (2011). doi:10.4049/jimmunol.1003174 
168. Offersen, R. et al.  A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances 
HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected 
Autologous CD4 + T Cells . J. Virol. (2016). doi:10.1128/jvi.00222-16 
169. Tsai, A. et al. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and 
65 
 
HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive 
Antiretroviral Therapy. J. Virol. (2017). doi:10.1128/jvi.02166-16 
170. Kessl, J. J. et al. HIV-1 Integrase Binds the Viral RNA Genome and Is Essential 
during Virion Morphogenesis. Cell 166, 1257-1268.e12 (2016). 
171. Forsbach, A. et al. Identification of RNA Sequence Motifs Stimulating Sequence-
Specific TLR8-Dependent Immune Responses. J. Immunol. (2014). 
doi:10.4049/jimmunol.180.6.3729 
172. Lorenz, R. et al. ViennaRNA Package 2.0. Algorithms Mol. Biol. (2011). 
doi:10.1186/1748-7188-6-26 
173. Iwanaszko, M. & Kimmel, M. NF-ΚB and IRF pathways: Cross-regulation on 
target genes promoter level. BMC Genomics (2015). doi:10.1186/s12864-015-
1511-7 
174. Boender, T. S. et al. Accumulation of HIV-1 drug resistance after continued 
virological failure on first-line ART in adults and children in sub-Saharan Africa. 
J. Antimicrob. Chemother. 71, 2918–2927 (2016). 
175. Etta, E. M. et al. High level of HIV-1 drug resistance mutations in patients with 
unsuppressed viral loads in rural northern South Africa. AIDS Res. Ther. 14, 36 
(2017). 
176. Abdool Karim, S. S. HIV-1 Epidemic Control — Insights from Test-and-Treat 
Trials. N. Engl. J. Med. 381, 286–288 (2019). 
177. Food and Drug Administration - FDA. Guidance for Industry. Cell Substrates and 
Other Biological Materials Used in Production of Viral Vaccines for Infectious 
Diseases Indications. U.S. Dep. Heal. Hum. Serv. Food Drug Adm. Cent. Biol. 
Eval. Res. Rockville. Estados Unidos (2010). doi:10.1089/blr.2006.25.697 
178. Bruner, K. M., Hosmane, N. N. & Siliciano, R. F. Towards an HIV-1 cure: 
Measuring the latent reservoir. Trends in Microbiology 23, 192–203 (2015). 
66 
 
179. del Toro Duany, Y., Wu, B. & Hur, S. MDA5—filament, dynamics and disease. 
Curr. Opin. Virol. 12, 20–25 (2015). 
180. Linehan, M. M. et al. A minimal RNA ligand for potent RIG-I activation in living 
mice. Sci. Adv. 4, e1701854 (2018). 
181. Barrat, F. J. et al. Nucleic acids of mammalian origin can act as endogenous 
ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. 
Exp. Med. 202, 1131–9 (2005). 
182. Chaturvedi, A. & Pierce, S. K. How location governs toll-like receptor signaling. 
Traffic 10, 621–8 (2009). 
183. Kuznik, A. et al. Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs 
and Imidazoquinolines. J. Immunol. (2011). doi:10.4049/jimmunol.1000702 
184. Brodin, J. et al. Establishment and stability of the latent HIV-1 DNA reservoir. 
Elife 5, (2016). 
185. Abrahams, M.-R. et al. The Replication-Competent HIV-1 Latent Reservoir is 
Primarily Established Near the Time of Therapy Initiation. bioRxiv 512475 (2019). 
doi:10.1101/512475 
 
 
 
 
 
 
 
 
67 
 
 
 
 
Appendices  
Primer Name Sequence (5’ à 3’) 
5’ LTRPA CCCACTGCTTAAGCCTCAATAAAGC 
GagR CTTACTTTTGTTTTGCTCTTC 
GagF GGAGCTAGAACGATTCGCAG 
B1F ATCCGGAGGCACGGGGCTCAAAGCCGCGAC 
B1R GTCGCGGCTTTGAGCCCCGTGCCTCCGGAT 
B2F ACGACGGCTCTCGGCCGGTAACAGTAACCC 
B2R GGGTTACTGTTACCGGCCGAGAGCCGTCGT 
B3F CTGCCCTGGTGAGCGCCATCAGCAACCCGA 
B3R TCGGGTTGCTGATGGCGCTCACCAGGGCAG 
B4F ATACGTGGCATTTCAGGAGGCGGCCGGAGG 
B4R CCTCCGGCCGCCTCCTGAAATGCCACGTAT 
Table 1. Primers used in this thesis 
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